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!ABSTRACT 
Colorectal cancer (CRC) is one of the most common cancers in Western countries and is the second 
most common cancer for both men and women in Australia.  Though 5-year CRC survival has 
significantly improved in recent years, incidence of the disease has remained relatively stable, 
therefore increasing the number of people living in CRC survivorship.  It is well understood that 
those living in CRC survivorship are at a heightened risk of again developing the disease.  
 
Though the mechanisms are still not clearly understood, physical activity (PA) levels and intensity 
are inversely related to the risk of CRC recurrence.  A potential factor involved in the relationship 
between PA and CRC development in CRC survivors is interleukin-8 (IL-8), a recognised 
molecular driver of cancer growth that can be influenced by exercise.  Further justifying the 
importance of PA to CRC survivors is its ability to improve aerobic fitness and body composition, 
two health parameters that are often poor in CRC survivors. The primary purpose of the present 
study was to examine the influence of exercise intensity on IL-8 in a sample of CRC survivors.  The 
secondary purpose was to examine potential changes in peak oxygen consumption (V̇O2peak) and 
body composition in response to exercise training completed at two different intensities. 
 
Eighteen CRC survivors were randomly assigned to either a high intensity interval training (HIIT) 
or moderate intensity training (MIT) group.  Participants completed three exercise sessions a week 
for eight weeks on a cycle ergometer. Each HIIT training session required participants to complete 
four intervals of 4 minutes each at 85-95% peak heart rate (HRpeak) while in each MIT session, 
participants completed 50 minutes of exercise at 70% HRpeak. Physiological testing was conducted 
at baseline (0 weeks), midpoint (4 weeks), and endpoint (8 weeks) of the intervention.  Physical 
activity and diet were controlled in the seven and three days preceding testing respectively.  
Physiological testing sessions included assessment of V̇O2peak and body composition using dual-
energy X-ray absorptiometry (DXA), with blood collected and analysed for plasma IL-8 
concentrations.  
 
IL-8 did not significantly change in either training group at any timepoint. However, secondary 
analysis of participants from both groups who had elevated baseline IL-8 concentrations (n=4) 
approached significance for the eight weeks of exercise training to reduce IL-8 values (P=0.068). 
V̇O2peak significantly improved in both HIIT and MIT groups after 4 weeks (26.6%, P=0.036 and 
3.0%, P=0.043 respectively) and 8 weeks (28.1%, P=0.015 and 7.2%, P=0.018 respectively).  After 
8 weeks, there was also a group-effect favouring HIIT for improvement in V̇O2peak (P=0.041).  Fat 
mass and body fat percentage were significantly lower in the HIIT group after 4 weeks (-3.7%, 
!P<0.01 and (-3.7%, P<0.01) and 8 weeks (-4.9%, P<0.01 and (-3.7%, P<0.01) compared to the MIT 
group where no changes were observed for either variable.   Similarly, lean mass increased in the 
HIIT group after 4 weeks (+2.2%, P<0.01) and after 8 weeks (+1.9%, P<0.01) but no change in lean 
mas was found for the MIT group at either timepoint. Changes in lean mass were greater for the 
HIIT group than the MIT group at 8 weeks (P<0.01). Reductions in fat mass were greater after 4 
weeks and 8 weeks for the HIIT group than the MIT group (P=0.046 and P=0.017 respectively).  
 
In summary, exercise failed to elicit significant changes in IL-8 in CRC survivors, likely due to 
baseline values in IL-8 being within normal ranges. The significant training-induced changes in 
V̇O2peak, fat mass, lean mass, and fat percentage found for the HIIT group are potentially clinically 
meaningful and important, as similar improvements in these markers have previously been 
associated with reduced cancer specific- and all cause-mortality. The present study has shown that 
HIIT appears to be a safe and effective mode of exercise for rapidly improving cardiorespiratory 
fitness and body composition in CRC survivors.    
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1.0 General Introduction 
The term ‘cancer’ describes a range of health conditions characterized by unmediated and 
uncontrolled cellular growth exceeding that of programmed cell death.  This deregulated tissue can 
infiltrate and harm healthy tissue throughout the body, likely resulting in major disruption to normal 
physiological function. In addition to the profound physical health implications to the individual, 
cancer is associated with significant psychosocial challenges to both the individual and their family 
and friends.   
 
Over 120 000 people are diagnosed with cancer each year in Australia[4] and approximately 50% of 
the population will be diagnosed with cancer some time in their life[4].   Colorectal cancer (CRC) is 
the second most common cancer in men and women in Australia[5].  Factors believed to increase 
the risk of CRC include low physical activity (PA) levels, poor diet, obesity, alcohol consumption, 
and tobacco smoking [6-12].  While there have been significant advancements in understanding the 
mechanistic underpinnings of CRC induction and progression[13], how lifestyle factors specifically 
influence the cellular and molecular drivers of CRC remains unclear.  
 
The ability to modify risk of CRC development through manipulating lifestyle factors is particularly 
important for people who have previously been diagnosed and treated for CRC.  CRC survivors are 
at a significantly higher risk of developing CRC again when compared to the risk of healthy 
individuals developing CRC for the first time[14, 15].  With improved awareness of the disease, 
improved detection of CRC, and more effective treatment strategies, the number of survivors is 
increasing; reducing recurrence of the disease in CRC survivors is therefore an emerging health 
focus.     
 
A potential biological mechanism that explains the relationship between PA and CRC risk involves 
interleukin-8 (IL-8).  IL-8 is believed to be intrinsically linked in the molecular processes of CRC 
and importantly, exercise has consistently been found to acutely influence IL-8 in healthy 
populations.  However, the chronic effects of exercise training on circulating IL-8 in any cancer 
population are far less studied[16, 17].   
 
CRC survivors are generally characterised by low levels of aerobic fitness and poor body 
composition[18].  Indeed, improvements in both aerobic fitness and body composition have been 
associated with vastly improved health parameters in a number of studies examining the benefits of 
exercise for cancer survivors[19].   
! 2 
 
The present study examines the response of IL-8 to moderate and high intensity exercise training in 
CRC survivors. Furthermore, the influence of exercise training at moderate and high intensities on 
aerobic fitness and body composition in the same population will be explored.   
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2.0 Literature Review 
2.1 Colorectal Cancer  
2.1.1 Epidemiology 
Cancer has long been a focal point of health research in the medical sciences and in 1996, the 
Australian Institute of Health and Welfare (AIHW) included cancer as a National Health Priority 
Area[20].  Of all the cancers, colorectal cancer (CRC) is one of the most common in Western 
countries[21] and is the second most common cancer for both men and women in Australia[5]. In 
2010 there were 14 860 new cases of CRC, a figure which has steadily risen in Australia over the 
past 30 years[22].  In the same year, 3 999 deaths from CRC were recorded, a decrease from 
previous years[22].  Thus, while the number of CRC cases is increasing (due to, amongst other 
factors, improved screening for the disease), patients are living longer following diagnosis and 
treatment.  
 
 When expressed as ‘disease burden’, CRC is second only to lung cancer in Australia in ‘disability 
adjusted life years’ (DALYs)[23].  DALYs reflect the cumulative number of years lost to premature 
death and number of years of healthy living lost to disability; in 2003, the total burden of CRC in 
Australia was estimated to be 63 605 DALYs[23].  Compounding the concern of such a high burden 
of the disease is that the number of clinical trials being conducted on CRC is disproportionally low 
when normalised for DALYs and compared to the number of trials being conducted with other 
cancers[23].  Despite having the second highest burden of disease of cancers in Australia, CRC 
ranks sixth in number of clinical trials having been conducted in cancer research[23].  Given the 
high incidence, prevalence and burden associated with CRC, research to better understand how to 
reduce the risk of CRC and improve outcomes for survivors of the disease is clearly warranted. 
 
Advances in public awareness, screening accuracy and/or treatment effectiveness have led to 
increases in five-year survival rate to 89.9% for localised CRC cases[24].  However, CRC survivors 
remain at an elevated risk of CRC recurrence compared to those who have not developed the 
disease [14, 15].  Additionally, Phipps and colleagues[14] report that survivors of CRC are more 
susceptible to secondary cancers at other sites including the lungs, stomach, kidneys, endometrium, 
and small intestine.  The combination of increasing incidence of CRC and survival rates following 
treatment has led to a growing number of individuals living at a heightened risk of CRC 
recurrence[15].  Of particular concern in this regard is the inconsistent advice and recommendations 
available to CRC survivors relating to those lifestyle behaviours known to influence risk of the 
disease recurrence[25].   
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2.1.2 Lifestyle Factors  
The risk of first time CRC development in the greater population is influenced by a number of 
lifestyle and biological factors.  Cross-sectional studies have identified low physical activity (PA) 
levels, poor diet, obesity, alcohol consumption, and tobacco smoking as significant factors 
increasing the risk of CRC [6-12].  Levels of PA appear to be particularly important; at least 15% of 
all CRC cases have been attributed solely to insufficient PA [26]. Furthermore, it has been 
estimated that a sedentary lifestyle increases CRC risk more than the risks associated with 
inadequate PA for any other cancer type[26].    
 
In a meta-analysis of 24 case-controlled and 28 cohort studies in CRC, it was consistently found 
that there was an inverse relationship between PA levels and CRC risk[27]. Such is the strength of 
the epidemiological literature, in 2006 the American Cancer Society included PA as a 
recommendation for reducing the risk of CRC[28].  However, given the lack of interventional data 
and thus specific details of the mechanistic relationship between PA and CRC risk, individuals 
seeking to reduce their risk of CRC are simply advised to increase the intensity and duration of their 
PA[28]. Complexity in developing disease-specific PA guidelines arises when one tries to quantify 
'high PA levels' with respect to frequency, duration, intensity and type, the cornerstones of exercise 
prescription.  Data from interventional studies involving PA are needed to inform the optimal 
combination of these variables and therefore ‘exercise dose’ to most effectively reduce CRC risk.     
 
There is convincing epidemiological evidence to suggest that vigorous activity elicits a greater 
reduction in CRC risk compared to activity performed at a moderate intensity[12, 29, 30].  White 
and colleagues[29], whose population-based case-control study found no statistically significant 
trend in risk reduction across groups of increasing total PA duration (hours/week), observed a 
significantly larger decrease in risk in those individuals who completed more vigorous PA. These 
findings suggest that high intensity PA reduces risk of CRC to a greater extent than lower intensity 
exercise.   
 
Despite the weight of research evidence showing that inactive people are at a higher risk of 
developing CRC and people who regularly undertake ‘high levels’ of PA have a reduced risk of 
developing CRC, much of the data have been derived from prospective studies in which activity 
levels were estimated from questionnaires[12, 30, 31].  Research is yet to accurately assess the 
specific relationship between exercise and risk of CRC recurrence. Six randomised control trials 
(RCTs) however have been conducted in a population of multiple cancer types, of which CRC was 
included. Unfortunately, results for the entire cohort were reported rather than for individual cancer 
! 5 
types precluding the examination of CRC in isolation.  These interventions varied greatly in overall 
intervention duration, session duration, intensity, frequency, and type of exercise however it was 
regularly noted that exercise could improve cardiovascular fitness[32, 33] muscular strength[32], 
self-reported physical functioning[32-36], levels of fatigue[32, 36, 37], inflammatory markers[37], 
and quality of life[32, 34, 36, 37].  So, whilst none specifically focussed on CRC survivors, nor was 
there consistency among interventions, the collective findings from these studies lend additional 
weight to the role of PA in improving the health of CRC survivors.   
 
Four studies have specifically examined the influence of exercise on the health outcomes in CRC 
survivors.  As summarised in Table 1, it was shown that exercise improved cardiovascular 
fitness[18, 38, 39]; reduced waist circumference and waist-to-hip ratio[18, 38]; reduced sum of 
skinfolds[18]; improved quality of life[39, 40]; improved functional capacity[38, 39]; and reduced 
levels of fatigue[38, 39].  These findings confirm that exercise has a central role in improving the 
overall health of CRC survivors. 
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Table 1:  RCTs Examining the Influence of Exercise Interventions on CRC Survivors' 
General Health  
Author n= Intervention Results 
Courneya et al. 
[40] 
INT = 69 
CON = 33 
INT: 16 weeks of moderate 
intensity (65-75% of age-
predicted maximum HR) 
exercise 3-5 times/week for 20-
30min.  Modality was self-
selected - walking, swimming, 
or cycling. 
CON: 16 weeks usual care. 
Improvements in 
cardiovascular fitness were 
positively correlated with 
improvements in quality of life. 
Bourke et al.[38] INT = 8 
CON = 9 
INT: 12 weeks of moderate 
intensity, 3 sessions per week 
lasting 30-60mins.  Exercise 
sessions included 30 minutes of 
aerobic exercise at 55-85% age 
predicted maximum HR 
followed by 2-4 sets of 8-12 
reps of resistance exercises. 
CON: Usual care 
Improvements in INT with 
FACT-F, functional capacity, 
aerobic exercise tolerance, and 
waist to hip ratio.  
No difference between groups 
in FACT-C scores. 
Pinto et al.[39] INT= 20 
CON = 26 
INT:  12 weeks of weekly 
telephone PA counselling as a 
weekly PA tip sheet. 
CON: Weekly telephone contact 
to administer a Symptom 
Questionnaire.  No PA 
instructions were made. 
PA recall levels were higher in 
INT group at 3 months but not 
6 or 12 months.  INT group 
experienced significant increase 
in estimated V̇O2peak after 
three months which was then 
maintained at 6 and 12 months; 
greater than CON at all three 
time points.  Both INT and 
CON experienced 
improvements in self-reported 
physical function, fatigue, and 
quality of life. 
Sellar et al.[18] INT = 20 
CON = 0 
INT: 12 weeks of combined 
aerobic and resistance training.  
3 sessions per week: 2 were 
combined aerobic and 
resistance, 1 was only aerobic. 
Improvements in V̇O2peak, 
strength, waist circumference, 
sum of skinfolds, and trunk 
forward flexion. 
INT: intervention, CON: control, HR: heart rate, NS: not significant, PA: physical activity, FACT-F: 
functional assessment of cancer therapy-fatigue, Fatigue FACT-C: functional assessment of cancer therapy-
colorectal 
 
Improvements in cardiovascular fitness are very important to the clinical situation of cancer 
survivors. Maximal aerobic capacity degrades significantly in CRC survivors throughout the 
disease-treatment continuum, attributable to the disease itself, disease-related symptoms, and 
treatment methodologies including surgery and chemotherapy[41-44].  The significance of a decline 
in V̇O2peak becomes apparent when examining the prognostic value of cardiovascular fitness for 
CRC survivors.  Compared to CRC survivors with a low maximal aerobic capacity, those with 
moderate to high levels of cardiovascular fitness have a significantly reduced risk of CRC 
recurrence [45].  Indeed, maximal aerobic capacity has long been inversely associated to all-cause 
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mortality, for an increase in aerobic fitness of 1 metabolic equivalent (MET), the risk of all-cause 
mortality reduces by 15% and 8% for men and women respectively[46, 47].  As such, greater 
improvements in maximal aerobic capacity will initiate better prognostic outlooks. 
 
The aforementioned associations suggest a dose-response relationship whereby greater increases in 
cardiovascular fitness result in more favourable health outcomes.   Given that high intensity interval 
training (HIIT) has been shown to elicit superior improvements in cardiovascular fitness compared 
to exercise training completed at lower intensities it is can be hypothesised that such training is of 
greater benefit to the individual[48].  Importantly, such is the case in clinical populations other than 
CRC survivors[48].  Whilst it is reasonable to assume such findings would be present in CRC 
survivors, research is yet to examine the influence of different training programs on cardiovascular 
fitness in this population.     
 
Like cardiovascular fitness, body composition plays a large role in determining the health of a CRC 
survivor.  Survivors of CRC are often characterised by poor body composition, including increased 
incidence of sarcopenic obesity (atrophy of skeletal muscle cells and hypertrophy of adipose 
cells)[49].  Such increases in fat mass and body fat percentage are clinically very important as these 
parameters have been positively associated with cancer risk as well as other significant 
comorbidities such as cardiovascular disease (CVD) [50, 51].  
 
Exercise is well established to aid in reducing fat mass[52].  The current literature-base and thus 
professional recommendations have long promoted moderate intensity aerobic exercise as the 
optimal form of exercise for reducing fat mass[52].  Paradoxically, moderate intensity exercise 
(approximately 65% V̇O2peak) induces a lower energy expenditure than HIIT[53]. However, the 
rate of fat oxidisation is far greater when exercising at a moderate intensity with a marked drop off 
in fat oxidization for exercise performed at intensities above 90% V̇O2peak[53]. Thus for two 
exercise sessions with equivalent energy expenditure, the one completed at a moderate intensity 
rather than a higher intensity will oxidise more fat. However, HIIT inherently has a higher total 
overall energy expenditure for a given time period, thus total fat oxidation will be a balance of total 
energy expenditure and rate of fat oxidisation. 
 
This intricate balance, and thus the effectiveness of different exercise intensities in eliciting changes 
in body composition, is yet to be specifically examined in CRC survivors.  The limited research 
measuring anthropometric data (as estimates for body composition) has been summarised in Table 
1.   
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Examined in only two instances, the influence of exercise body composition is a very under 
researched area for CRC survivors[18, 38].  Further clouding this research is that both studies used 
a combination of resistance and aerobic exercise.  Whilst this provides excellent ecological validity 
and their work should be commended, it precludes understanding of each individual exercise type.  
This is especially the case where anthropometric measures were used as a surrogate to body 
composition measures.  To achieve a strong scientific understanding, research must be conducted 
with only one exercise type with variations in intensity within that exercise type to determine 
optimal prescription for these individuals. 
 
In the first study to date, waist-to-hip ratio was found to significantly reduce in CRC survivors 
following 12 weeks of combined moderate intensity aerobic exercise and resistance training[38].  
Participants completed three sessions per week, which included 30 minutes of aerobic exercise at 
55-85% age, predicted maximum heart rate (HR) followed by 2-4 sets of 8-12 reps of resistance 
exercises.  Such results are not surprising given participants were completing moderate intensity 
exercise, the recommended intensity for weight loss as previously discussed.  However, the 
inclusion of resistance exercise and employment of measurement tools that concern anthropometry 
rather than body composition justify a need for further research.  To document the ability for 
exercise to reduce fat mass, the study should only perform aerobic exercise and have body 
composition measured directly and accurately such as by dual-energy X-ray absorptiometry (DXA).        
 
Waist circumference and sum of skinfolds were found to significantly decrease following twelve 
weeks of combined aerobic and resistance training by Sellar et al.[18].  Interestingly though, when 
assessed by air displacement plethysmography no significant change in fat mass, body fat 
percentage, or muscle mass were observed[18].  Participants in this study were required to complete 
three sessions a week of aerobic cycle ergometry at 60-75% peak power output however HIIT 
began to replace the MIT after week 5.  Two of the exercise sessions per week also included a 
whole body resistance exercise circuit.  This research by Sellar er al[18] again provides positive 
suggestions for the role of exercise in manipulating body composition in CRC survivors.  This 
study also introduces the idea that HIIT could still elicit changes in body composition in this 
population.  However, with confounding factors such as having participants perform both aerobic 
and resistance exercise as well as contradictions in findings based on the measuring instrument 
used, more research is required in this area.   
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Given the paucity of, and discrepancy within, the current findings further examination of how 
exercise can manipulate body composition variables in cancer survivors is warranted.  The specific 
shortcomings of previous research is in the mixture of aerobic and resistance exercise and in testing 
methodology.  The requirement of future research is to examine aerobic exercise alone given its 
inherent association with fat oxidisation and in turn body composition.  Within aerobic exercise, 
moderate intensity exercise is widely regarded to be superior in eliciting reductions in fat mass for 
equal energy expenditure due to the increased rate of fat oxidisation occurring when exercising at 
this intensity.  However previous research into CRC survivors has purported that HIIT may have a 
role to play in fat reduction, suggesting the inherently greater total energy expenditure at this 
intensity may offset its lower rate of fat oxidisation [18].  Thus, a dichotomous research approach, 
which compares the effectiveness of these intensities, is indicated.  This study should then ensure 
body composition is measured most directly and accurately such as by DXA. A study designed in 
this way would be able to determine the optimal aerobic exercise prescription to counter sarcopenic 
obesity via reductions in fat mass.  
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2.1.3 Biological Markers  
Despite the available literature showing that regular exercise improves numerous health outcomes 
with CRC survivors, details of the relationship between exercise and CRC risk are not well 
understood.  This is understandable since calculations of risk commonly use incidence rates in the 
succeeding years and require very large sample sizes.  Furthermore, the justification of a 
prospective trial to accurately gauge risk of relapse should be preceded with evidence showing that 
exercise can induce significant benefits to factors associated with risk of CRC. Establishing optimal 
target outcomes will also allow for RCTs to accurately quantify the influence of variables. One such 
variable that requires investigation is exercise intensity and how this may be related to the 
mechanisms influencing CRC.  Thus, potential biological markers linked to CRC that may be 
influenced by exercise need to be examined in an RCT before disease-specific PA guidelines can be 
developed.   
 
A number of studies have sought to identify potential biomarkers associated with CRC risk[54-56].  
Given the multifocal and complex nature of cancer, it is generally accepted that there is no single 
biomarker that provides a complete diagnostic or prognostic evaluation of disease risk[57].  Indeed, 
the advancing fields of genomics, proteomics, and bioinformatics create a vast and intricate 
scientific landscape of several factors and biomarkers known to be associated with CRC[58].   
 
In light of the documentation of the human genome and the progress made in describing the 
proteomic equivalent, known as The Human Protein Initiative, much of the recent CRC research 
has concerned itself with serum sampling for proteomic or genomic analysis[54, 56, 57, 59, 60].  
For a published review of one possible family of proteins that contribute to CRC, the insulin-like 
growth factor axis, please see Appendix 5.1.  Another potential target area for CRC interventions is 
cytokines, a small class of proteins vital for immune system regulation.  These biochemical factors 
have a range of regular immune functions including anti-tumour activity[61]. However, 
deregulation of cytokine production or activity can lead to detrimental accelerations in 
inflammation, angiogenesis and cell proliferation, thus rendering cytokines as cancer-promoting 
factors[61-63].  Furthermore, in situations whereby cancer cells are pre-existing, an abundance of 
cytokines can stimulate tumour growth and cell proliferation[61].  As such, it is believed that 
chronically elevated serum cytokines regulate, at least in part, tumour development and progression.   
 
Of the cytokines, interleukin-8 (IL-8) has attracted considerable interest in the field of cancer 
research, including that of CRC [64-66]. While others, such as IL-6, tumour necrosis factor-alpha 
(TNFα), C-reactive protein (CRP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-
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9 (CA 19-9) have been examined by researchers, IL-8 distinguishes itself from other cytokines 
through its multiplicity of oncogenic roles of angiogenesis, mitogenesis and inflammation[67, 68].   
In addition, circulating IL-8 levels show incremental increases as a person moves from normal 
health, to colorectal adenomas, and then through the stages of CRC (epithelial IL-8 concentrations 
in adenoma and adenocarcinoma were found to be 114% and 159% of control respectively); this 
suggests that IL-8 has a regulatory role in CRC [64-66, 69].  IL-8 has also been shown to contribute 
to the pathogenesis of other conditions including secondary cancers and cardiovascular disease[1, 
14, 70-72]. Not only do low levels of PA and poor diet increase the risk CRC, they also increase the 
risks of type two diabetes; CRC survivors are thus likely to be at a greater risk of developing these 
other diseases and conditions[73]. As such, research into factors that influence circulating IL-8, and 
in turn these health conditions, warrants investigation[14].   
 
While research is yet to investigate the effects of exercise on IL-8 in any CRC population, there is 
research to suggest that exercise training can improve circulating IL-8 levels in clinical populations 
such as those with metabolic syndrome [16].   
 
Exercise has been shown to influence the levels of several different serum proteins (many being 
similar in chemical structure to IL-8) in CRC survivors.  As summarised in Table 2, exercise has 
been shown to mediate changes in interleukin-1 receptor antagonist (IL-1ra)[74], resting insulin, 
and insulin resistance (HOMA-IR) and increase IGF binding protein 3 (IGFBP-3) with CRC 
survivors – changes that favour a reduction in CRC risk given the roles of each variable within the 
body and CRC tumour progression[75].  In addition, tumour necrosis factor alpha (TNF-α) was 
shown to decrease following a 12 week home-based exercise intervention[75]. However, no 
changes were observed following a 14 day exercise intervention[74].  The influence of exercise on 
serum cytokines, and in particular, IL-8 with CRC warrants further research.  
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Table 2:  RCTs Examining Influence of Exercise Interventions on Serum Cytokines in CRC 
Survivors 
Author n= Intervention Results 
Allgayer et al. 
[74] 
Mod=13 
Low=10 
2 weeks of 40 min of either 
moderate (55-65% V̇O2peak) or 
low intensity (30-40% V̇O2peak) 
exercise every day. 
IL-1ra response to exercise 
decreased in moderate intensity 
group but not low intensity 
group after intervention. NS 
changes in IL-1β, IL-6, TNF-α, 
sTNFI/II in both groups. 
Lee et al. [75] Frequent 
INT= 8 
Less 
Frequent 
INT = 9 
12 week home-based exercise 
program. 
Frequent INT:  Participants were 
provided one supervised 
exercise session for first three 
weeks plus high levels of 
education and regular support 
from practitioners throughout 
the twelve weeks 
Less frequent:  Participants were 
provided with limited education 
and support over the 12 week 
period. 
Both groups significantly 
increased vigorous PA levels 
with no difference between 
groups. 
Significant reductions in body 
mass, insulin, HOMA-1R, and 
TNF-α whilst significant 
increases in IGF-1, adiponectin, 
and IGFBP-3 were observed 
when data from both groups 
was collated. 
INT: intervention, NS: not significant, PA: physical activity, IL-1ra: interleukin-1 receptor antagonist, 
HOMA-IR: homeostatic model assessment-insulin resistance, IGF-1: insulin-like growth factor 1, IGFBP-3: 
insulin-like growth factor binding protein 3, TNF-α: tumour necrosis factor-alpha, Mod: Moderate intensity 
group, Low: Low intensity group. 
 
Given the evidence implicating IL-8 in CRC tumour progression coupled with the data showing 
changes in IL-8 with exercise, research that specifically examines changes in IL-8 with exercise in 
CRC survivors is warranted.   
 
2.2 Interleukin-8  
IL-8, also known as CXCL8, is a cytokine from the CXC chemokine family encoded by the IL-8 
gene[1].  The ligand IL-8 is characterised by 72 amino acids with four cysteine molecules whereby 
a single amino acid separates the first two cysteines, hence the nomenclature “CXC”[2].  Clark-
Lewis[2] went on to document the full sequence of IL-8 illustrating this structure, as shown in 
Figure 1.   
 
!
Figure!1.!Sequence!of!Interleukin28.!!The!72!amino!acid!sequence!of!IL28!is!shown!with!cysteine!molecules!
indicated!with!arrowheads!and!the!ELR!motif!identified!by!a!star[2].!!!
*!
! 13 
IL-8 is primarily produced by monocytes and macrophages, however any tissues with toll-like 
receptors such as muscle and fat also possess the capacity to produce it[76-78].  A wide range of 
stimuli can drive IL-8 production including stress of the microenvironment, inflammatory 
signalling, and steroidal hormones[1].  Such drivers induce ligands that can bind to toll-like 
receptors and initiate a cascade of neutrophil activation and in turn IL-8 production[79].  
 
Following production, IL-8 can be secreted into circulation and attend sites of damage as a part of 
the immune response.  IL-8 exerts its biological influence by binding to extracellular 
transmembrane G-protein coupled receptors CXCR1 and CXCR2 [80]. IL-8 is the only molecule 
that can bind to CXCR1 and does so with greater affinity than it does to CXCR2, a receptor which 
is also open to any chemokine that possesses the ELR motif, as indicated in Figure 1[80, 81]. These 
IL-8 receptors are most commonly found on monocytes and neutrophils whilst presentation is also 
found on the cell walls of neurons, cancer cells, and endothelial cells[82-88].  Thus, the range of 
target for IL-8-induced responses is quite broad. Once IL-8 binds to these target cells it can 
propagate many intracellular processes including inflammation, cell proliferation, angiogenesis, and 
chemotaxis[89, 90].  It is thought that self-regulation of IL-8 activity occurs via dimerization when 
IL-8 concentrations reach certain levels[91]. This dimer form of IL-8 is biologically inactive in that 
it is unable to bind to the N-domain of the CXCR1, thus blocking signalling via this receptor[91].  
However, research suggests that this dimer form of IL-8 can still stimulate CXCR1 to a limited 
extent[92].  The ability for the dimer form to activate CXCR2 is comparable to that of the 
monomer[92]. 
 
2.2.1 Interleukin-8 and Mechanisms of Colorectal Cancer 
While cross sectional studies have shown IL-8 to be intrinsically linked with CRC[64, 66, 93], 
mechanistic research has found CRC cells present with CXCR1 and CXCR2 receptors thus 
allowing IL-8 to directly exert its biological potential on these cells[67, 94]. The cellular events 
involving IL-8 that result in mitogenesis and angiogenesis have recently been reviewed by Waugh 
and Wilson[1]. These pathways are shown in Figure 2 and Figure 3, respectively[1]. Figure 2 
depicts the complex cascade of events from initial IL-8 signalling at the cell wall through to 
eventual gene expression to drive cell proliferation and survival while Figure 3 illustrates the role 
of IL-8 in the microenvironment to predominantly facilitate angiogenesis.  This shows how IL-8 is 
involved downstream in mitogenesis and angiogenesis.  Aspects of these processes are reviewed in 
greater detail in the following sections.  
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Source:! Waugh! and! Wilson[1].! Figure! 2.! Characterised! IL28! Signalling! Pathways.! ! A! schematic! diagram!
illustrating! the! range! of! signalling! pathways! that! are!activated!after! stimulation!of!CXCR1! and/or!CXCR2!
receptors!with!IL28.!These!signalling!pathways!have!been!shown!to!promote!protein!translation!(left)!and!
regulate! the! activity! of! a! range! of! transcription! factors! (bottom).! Solid/ bold/ lines:/ transcription! factors!
whose!activity!has!been!shown!to!be!positively!regulated!by! IL28!signalling!using!various!reporter!assays.!!
Dashed/lines:/the!putative!pathways!through!which!IL28!signalling!regulates!transcription!factor!activity[1].!
!
! 15 
 
 
 
  
Source:! Waugh! and! Wilson[1].! Figure! 3.! The! Role! of! IL28! Signalling! in! the! Tumour! Microenvironment.!
Tumour2derived! IL28! has! the! capacity! to! exert! profound! effects! on! the! tumour! microenvironment.!!
Tumour2derived!IL28!will!activate!endothelial!cells!in!the!tumour!vasculature!to!promote!angiogenesis!and!
induce!a!chemotactic!infiltration!of!neutrophils!into!the!tumour!site[1].!
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2.2.2 Interleukin-8 and its Involvement with Mitogenesis and Angiogenesis in Colorectal 
Cancer 
Cancer is characterised by cell proliferation exceeding cell apoptosis.  As such, in normal cell 
functioning, a delicate balance between proliferative and apoptotic factors exists and an imbalance 
towards the former can result in tumorigenesis.  As previously described, IL-8 is a cytokine with 
proliferative qualities whose overexpression has been found to correlate with CRC and its 
progression[3, 64, 66].   
 
Cancer cells, which have both CXCR1 and CXCR2 receptors, receive IL-8 via autocrine, paracrine, 
and endocrine avenues[3]. The binding of this IL-8 to CRC cells triggers a number of intracellular 
pathways, ultimately leading to proliferation[95].  Although the exact mechanisms underlying this 
phenomenon are not comprehensively understood, a review of potential molecular pathways has 
been included in Appendix 5.2.  A consequence of these IL-8 triggered pathways appears to be 
stimulation of transcription factors with the principal task of transcribing cell proliferation genes[1, 
3, 96].  Further suggesting IL-8’s involvement in cell proliferation as an autocrine mediator, is that 
as IL-8 expression increases inside a CRC cell there is a concomitant increase in cell proliferation 
[95].  So whilst the exact mechanism linking IL-8 and mitogenesis in CRC is yet to be identified, 
the available evidence supports the existence of such a link. 
 
Along with mitogenesis, one of the major mechanisms of cellular growth, in normal biological 
functioning and in cancerous tissue, is angiogenesis[97].  With the formation of new blood vessels 
comes a greater ability for delivery of nutrients, oxygen, growth factors, and other blood-borne 
elements [97].  Initiated very early in tumour life, angiogenesis is essential to the progression and 
growth of any tumour, including that of CRC[97-99]. CRC-induced angiogenesis is stimulated by 
angiogenic factors, such as IL-8, binding to receptors on endothelial cells in the 
microenvironment[99, 100].  The ability of IL-8 to exert its angiogenic potential on endothelial 
cells has been demonstrated both in vitro and in vivo[89, 101, 102].  Interestingly, the effectiveness 
of IL-8 to induce angiogenesis in endothelial cells is more pronounced in microvasculature than 
macrovasculature[103]. 
 
Endothelial cells have been found to exhibit both CXCR1 and CXCR2, however there is suggestion 
that only the CXCR2 receptor possesses the capacity to initiate angiogenic process[104, 105]. Any 
chemokine displaying the ELR motif has the potential to bind to CXCR2 and initiate this process, 
however the abundance of IL-8 produced by the surrounding CRC cells means that it is a potent 
angiogenic factor[104, 105].   
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The intracellular process driving angiogenesis is the same as that of proliferation with the additional 
property of control and direction[106].  Rather than proliferating in a random fashion as is the case 
in cancer cells, angiogenesis involves the systematic breakdown of the extracellular matrix to direct 
the proliferation of endothelial cells in certain directions and structures necessary for new vessel 
formation[107]. Of interest is that IL-8, in vitro, can up-regulate the factors responsible for this 
breakdown, further implicating IL-8 as an angiogenic promoter[107].  This phenomenon has been 
demonstrated in vivo in melanoma, prostate cancer, lung cancer, and Kaposi’s sarcoma[108-111].  
Whilst no data for CRC exist, it is reasonable to assume that endothelial cells in the CRC 
microenvironment would show similar properties. Moreover, Ning et al[112] demonstrated in vivo 
that CRC cells transfected with IL-8 induced angiogenesis in the microenvironment.  
 
As such, IL-8 is a potent mitogenic and angiogenic stimulator, demanding the investigation for 
interventions with the ability to manipulate this variable.  One such method previously discussed in 
this review is exercise and physical activity.  
2.3 Interleukin-8 and Exercise 
The available evidence supports relationships between IL-8 and CRC as well as PA and CRC 
risk[30, 65].  What remains to be potentially established is an exercise-induced mechanism that 
changes circulating IL-8 levels in CRC survivors. It has been well documented that exercise has a 
major role in the manipulation of cytokines[113]. Indeed, numerous studies have shown that a 
single bout of exercise can alter circulating levels of IL-8, however relatively few studies have 
examined the changes in IL-8 in response to exercise training[16, 114, 115].  It is imperative that 
such research is conducted with CRC survivors to best assist their health and risk of recurrence.   
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2.3.1 Interleukin-8: The response to Exercise Training 
Given the intrinsic link between resting levels of IL-8 and CRC, it is particularly important to 
understand whether exercise training can be used as a potential normalising agent.  Very few 
studies have examined the effect of exercise training on circulating IL-8 and the findings have been 
mixed, especially within clinical populations.  There are suggestions, however, that exercise can 
normalise circulating IL-8 concentrations[16, 17].   
 
Troseid and colleagues[16] examined changes in plasma IL-8 in nine patients with metabolic 
syndrome, another disease associated with inflammatory mechanisms, in response to 12 weeks of 
exercise training.  Thrice weekly exercise sessions each lasted for 45-60 minutes and included a 
combination of aerobic (walking/running) and resistance exercises. Although exercise intensity was 
not carefully controlled, training resulted in a significant (p=0.009) reduction of IL-8 from baseline; 
no change was observed in the control group (n=6).   
 
It is theorised that such a reduction could be due to a multitude of factors. One potential mechanism 
is a reduction in IL-8 released from the muscle during exercise.  Given that hypoxia is the primary 
trigger of IL-8 production during exercise, it is reasonable that following exercise training, 
improved delivery of oxygen to the exercising muscles coupled with greater mitochondrial volume 
will result in less hypoxic stress.  As such, muscles will produce less IL-8. This is supported by 
numerous studies showing that athletic populations characterised by greater levels of aerobic fitness 
have dampened immune responses to exercise than sedentary counterparts[114, 116-118].  
Similarly in older adults, Della Gatta et al.[17] recently examined the influence of exercise training 
on the acute intramuscular IL-8 response.  Eight older adults (age range 60-75 years) completed 
three sessions of resistance each week for 12 weeks.  Each session consisted of two sets of 8-12 
repetitions of six multi-joint exercises with intensity increasing from 50% of 1 repetition maximum 
(1-RM) in week one to 80% 1-RM in week six which was then maintained through to week 12. The 
authors found IL-8 expression in the muscle to be significantly reduced (p<0.001) two hours post-
exercise following 12 weeks of training.  A similar trend, though not statistically significant, was 
found following six weeks of high intensity interval training by Croft and colleagues in healthy 
individuals[119].  Participants (n=5) completed four sessions per week involving five x 3 minute 
bouts of running at 90% V̇O2max interspersed with 3 minutes recovery. Plasma IL-8 tended to be 
lower immediately post-exercise compared to pre-training values however, neither intramuscular 
nor time course measures were reported[119]. Whether or not this can result in a lowering of 
circulating levels of IL-8 over time is yet to be determined.    
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Another mechanism that may contribute to a decrease in circulating IL-8 levels in response to 
exercise relates to changes in body composition. IL-8 can be classed as an adipokine, as it is 
produced by adipocytes.  Indeed, obesity has been associated with higher levels of circulating IL-
8[120, 121]. It would thus be reasonable to assume that reductions in fat mass that may occur in 
response to exercise training, may dampen IL-8 expression and in-turn reduce circulating levels.  In 
line with this, the reductions in IL-8 found by Troseid and colleagues[16] were related to reductions 
in body mass index (BMI) and waist circumference.  However, it must be acknowledged that there 
is conjecture in the literature over whether the IL-8 produced in adipocytes reaches circulation and 
contributes to systemic levels[122]. Despite this, the interplay between the changes in IL-8 and 
body composition in response to exercise training is one that warrants further investigation.   
 
Surprisingly, there exists little research documenting changes in body composition in response to 
exercise training with CRC survivors.  Of the limited number of studies that have examined body 
composition, most have simply reported BMI, waist-to-hip ratio, and/or skinfolds[18, 38, 39]. To 
date, the best documentation of body composition in CRC survivors completing an exercise 
intervention was provided by Sellar et al.[18] who used air displacement plethysmography testing 
in their investigation.  Their 27 participants all completed three exercise sessions per week, two of 
combined aerobic and resistance exercise on top of one purely aerobic session.  It was found that 
estimations of fat mass and body fat percentage both showed non-significant downward trends over 
time (p=0.152 and p=0.171, respectively)[18].   Despite methodological shortcomings of the study 
by Sellar et al.[18] such as an intervention of both aerobic and resistance training and no control 
group, the conduction of future research into body composition is required. Such further studies will 
allow inferences to be drawn as to whether changes in body composition resulting from exercise 
may, at least in part, explain potential changes in IL-8.   By understanding the pathways by which 
exercise influences IL-8, health professionals will be able to prescribe and recommend exercise in a 
way optimised to reducing IL-8 and in turn CRC risk.   
 
It is also worth recognising that exercise training has not always been found to elicit a reduction in 
IL-8[123].  In a study conducted by Gomez et al.[123] in breast cancer survivors (n=8), no 
significant difference in IL-8 was found following 8 weeks of combined aerobic and resistance 
training.  However, by the author’s admission their sample size and cytokine testing methodology 
could have precluded the detection of significant results[123].   
 
In summary, the available evidence suggests that IL-8 is involved in the development of CRC, 
whilst exercise appears to impart a normalising effect.  However, much of the current IL-8 research 
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has been in healthy or athletic populations.  The few studies that have examined changes in IL-8 
with exercise in clinical populations have shown promise yet have lacked the methodological rigor 
to conclusively detect statistically significant findings. Furthermore, the mechanism underlying how 
a period of exercise training might affect IL-8 level requires further investigation.  Research that 
controls for, and examines the response of, IL-8 to different exercise intensities with consideration 
for changes in body composition and aerobic fitness is needed.  These findings will inform the 
development of PA guidelines for CRC survivors that most effectively reduce the risk of recurrence 
of the disease. 
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3.0 The Effects of High Intensity Interval Training on Interleukin-8 in 
Colorectal Cancer Survivors 
3.1 Research Aims and Hypotheses 
The primary aim of the present study was to determine how exercise training at two different 
intensities would influence IL-8 in CRC survivors.  The secondary aims were to examine potential 
changes in V̇O2peak and body composition in response to high and moderate intensity exercise with 
the same population. 
 
It was hypothesised that exercise training would reduce circulating IL-8 and that there would be 
greater reductions following high intensity interval training compared to continuous moderate 
intensity training.  In addition, it was hypothesised that HIIT would result in greater improvements 
in V̇O2peak compared to moderate continuous intensity training.   It was expected that reductions in 
fat mass and body fat percentage would be greatest in the MIT group whilst the HIIT group would 
have the greatest improvements in muscle mass.   
3.2 Methods 
3.2.1 Participants 
Eighteen women and men who had been previously treated for CRC were invited to participate in 
this randomized controlled trial. Each was recruited from an existing Cancer Council Queensland 
(CCQ) CRC registry and inclusion criteria for the study were: 
      i.         aged over 18 years; 
     ii.         not being medicated with insulin; 
   iii.        free of any musculoskeletal, neurological, respiratory, metabolic or cardiovascular 
conditions that prevent safe completion of the exercise demands of the study. 
 
3.2.2 Recruitment 
Participants were recruited by the following methods: 
1.  Individuals who had previously contributed to a longitudinal study investigating quality of life in 
CRC survivors were sent a letter of invitation by the Cancer Council Queensland.  Those meeting 
the criteria of the study were directed to contact the Principal Investigator of the current study to 
express their interest in participating.  A CONSORT flow diagram of participants recruited via this 
method is shown in Figure 4. 
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Figure 4.  CONSORT Flow Diagram of recruitment via Cancer Council Queensland letters of 
invitation. 
2. Queensland Cancer Registry (QCR): The QCR is a population-based registry for almost all 
individuals diagnosed with cancer in Queensland. The QCR procedure for recruitment included 
identification of individuals within the QCR aged 18 to 75 years with a histologically confirmed 
diagnosis of colorectal cancer (ICD0:C18-C20, C218) between 1st January 2005 and 31st 
December 2012. Patient names and the names of their treating doctor were obtained from the QCR 
database and entered into a customised study database. A letter requesting permission for their 
patient to be approached was sent to the treating doctor, followed by reminder telephone calls 
where necessary. Initially, all individuals meeting the aforementioned criteria diagnosed in 2012 
were sent out a letter.  Once recruitment began to subside, letters were then sent out to all those 
diagnosed in 2011, and so on. After this was returned, patients were forwarded a study information 
sheet and a letter from their doctor informing them of the study. The information flyer included 
details and instructions for contacting the Principal study investigator to discuss the study in detail, 
their eligibility and possible participation.  A CONSORT flow diagram of participants recruited via 
this method is shown in Figure 5. 
CCQ!leTers!of!invitaUon:!276!
Phone!
responses:!41!
Randomised:!3! Declined!to!parUcipate:!38!
Distance:!21!
MedicaUon:!1!
Time:!12!
Intensity:!4!
Email!
responses:!19!
Randomised:!2! Declined!to!parUcipate:!15!
Distance:!7!
MedicaUon:!0!
Time:!4!
Intensity:!0!
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Figure 5: CONSORT Flow Diagram of recruitment via Queensland Cancer Registry. 
3. Cancer Council Queensland Cancer Helpline: Individuals previously diagnosed with colorectal 
cancer above the age of 18 who contacted the Cancer Helpline were provided a brief explanation of 
the study and asked to consider participation. Callers who express an interest were mailed a study 
information flyer and a brief letter from the Head of Research at Cancer Council Queensland. The 
information flyer included details and instructions for contacting the Principal study investigator to 
discuss the study in detail, their eligibility and possible participation.  
4. CCQ support groups and contacts: Information about the study and the contact details of the 
Principal investigator were posted on the CCQ’s website and included in CCQ newsletters, and 
CCQ volunteer network emails and newsletters. Cancer Support Groups were also asked to advise 
their members of the study both during meetings and in newsletters. 
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A CONSORT flow diagram of participants recruited via methods 3 and 4 is shown in Figure 6.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6: CONSORT Flow Diagram of recruitment via the Cancer Council Queensland Helpline and Support Groups. 
 
All individuals who contacted the Principal Investigator were first assessed to determine whether 
they met the eligibility criteria. Those eligible were sent a copy of the participant information sheet, 
medical history form, and the doctor’s consent form.  Participants were asked to complete these 
forms and return them to the Principal Investigator at the first face-to-face session (familiarisation 
session).   If these were not completed the participant was not allowed to partake in any exercise 
and would need to reschedule the session. 
Ethical approval was obtained for this project through both The University of Queensland’s 
Medical Research Ethics Committee (#2013000749) and the Queensland Public Health Act 
(#RD004846). 
3.2.3 Protocol 
Colorectal cancer survivors participated in either a high intensity interval (HIIT; n=9) or moderate 
intensity (MIT; n=9) exercise-training program. Participants completed 24 training sessions of their 
respective intensities; three sessions per week were held over the eight weeks. In order to track 
changes in IL-8, body composition, and aerobic fitness across the intervention, participants 
completed a series of tests at baseline, midpoint (following 12 sessions and four weeks of training), 
and endpoint (following 24 training sessions and eight weeks of training).  This testing battery 
included the sampling of venous blood for the later measurement of resting IL-8 concentration; 
anthropometric measures of height, body mass, and a dual-energy X-ray absorptiometry (DXA) 
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scan; and a V̇O2peak test on an electronically braked cycle ergometer. This testing battery was all 
completed in a single testing session and in a standardized order.  Four days or more prior to 
baseline testing, participants completed a familiarisation session.  
Familiarisation 
After recruitment and acceptance into the study, participants returned their completed medical 
history form and the doctor’s consent form at the familiarisation session. The familiarisation session 
was conducted seven days prior to their baseline testing session. This session served to familiarise 
the participant with the environment, equipment and testing procedures.  This included a test to 
determine V̇O2peak on an electronically-braked cycle ergometer (Lode Excalibur Sport, Lode B.V., 
Groningen, Netherlands).  Inclusion of this test was deemed necessary given the recent findings by 
Scott et al. [124] examining the reproducibility of maximal cardiopulmonary exercise testing in 
men with prostate cancer. Scott et al. [124] found high correlations in test-retest results however 
there was still a significant improvement from the first to the second maximal cardiopulmonary 
exercise test, indicating performing only one maximal cardiopulmonary exercise test would not 
yield accurate results.  The protocol for this test is detailed below.  
 
Baseline Testing 
Control Measures 
Prior to each testing session – baseline, midpoint and endpoint – participants were 
asked to follow a number of control measures. 
 
Physical Activity & Diet Control:  Each was asked to record their food consumption for three days 
and physical activity for seven days preceding each testing session; diaries for recording these data 
are shown in Appendices 8.4 and 8.5, respectively). In advance of all subsequent testing sessions, 
participants were asked to reproduce these behaviours as closely as possible; copies of the diaries 
were retained by the participants for their future reference. Furthermore, in the 24 hours preceding 
each testing session (except the familiarisation sessions), participants were asked to: (a) abstain 
from caffeine consumption; (b) abstain from alcohol consumption; (c) abstain from vigorous 
exercise; and (d) maintain a hydrated state.  In the 12 hours prior to the testing sessions, they were 
requested avoid consuming food, drink, and other consumables with the exception of water and 
prescribed medications.  Upon arrival at the laboratory for testing, each was asked to confirm via 
checklist that the pre-exercise criteria had been met.  For midpoint and endpoint testing, this 
checklist also included of the three-day food diary (Appendix 5.5) and seven-day physical activity 
diary (Appendix 5.6).  To assess replication a number of factors were examined.  The three key 
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elements of the diet that would have potentially influenced exercise performance between testing 
sessions are total energy, total CHO and total protein.  Replication was assessed as + 10% for each 
of these components across the three days on each testing occasion.   Similarly, for physical activity 
the three key elements were total number of activities, activity duration, and activity intensity.  
Using the formula from the Godin Leisure-Time Exercise Questionnaire [125], these factors could 
be translated to a single number.  A + 10% tolerance was placed on this final score.  Additionally, 
consideration was given to the timing of exercise sessions. For example, a participant who 
completed a week’s worth of exercise in the last three days of the week would not be considered to 
have acceptably replicated their physical activity levels despite having a similar score for that seven 
day period.  In the instance where not all of the aforementioned criteria were met, the testing 
session was rescheduled.  Physical activity levels were also assessed at baseline as a descriptive 
characteristic using the Godin Leisure-Time Exercise Questionnaire[125].  
Outcome Measures 
Biological Markers: Using a 21 G needle, a qualified phlebotomist collected a 5 mL resting venous 
blood sample into a 6 mL spray-coated K2EDTA vacutainer (BD Vacutainer, Becton, Dickinson 
and Company, New Jersey, USA).  Samples were then immediately centrifuged with force at a 
relative centrifugal for 10 minutes at 900 g, from which plasma was extracted into 0.6 mL aliquots 
and stored in 0.6 mL Eppendorf (PCR Tubes, Neptune Scientific, San Diego, USA) at -80°C.  
These samples were analysed in duplicate at the completion of the study.  Detection of IL-8 in 
plasma samples was completed using enzyme-linked immunosorbent assay (ELISA) kits as per 
manufacturer’s instructions by a trained laboratory technician (R&D Systems, Human CXCL8/IL-8 
Quantikine ELISA Kit, Minneapolis, USA) (co-efficient of variation (CV) = 11.2%). 
 
Body Composition:  Body mass and height were measured using an electronic, calibrated scale 
(Seca, Birmingham, UK) and stadiometer (Seca, Birmingham, UK), respectively. Body 
composition (i.e. regional and whole body lean and fat mass) for each participant was measured 
using DXA (Hologic Discovery A, Waltham, MA) (CV = <1.1%). Participants lay on the DXA 
scanning table for approximately 7 minutes and a scanning arm moved above their body. A low-
dosage x-ray passed from underneath the table to the scanning arm.  A qualified DXA technician 
conducted and analysed all DXA scans.  
Peak Aerobic Power (V̇O2peak): Upon arrival at the laboratory, resting heart rate (HR) (Suunto 
Ambit2 S heart rate monitor, Suunto Oy, Vantaa, Finland) and blood pressure (BP) using a blood 
pressure cuff (Durashock Sphygmomanometer, Welch Allyn, New York, USA) measures were 
recorded. The V̇O2peak test required participants to progressively cycle on an electronically-braked 
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cycle ergometer to volitional fatigue; oxygen consumption (V̇O2) and carbon dioxide production 
(V̇CO2) were measured continuously during exercise. Expired air was analysed for fraction of 
expired oxygen (FEO2) and fraction of expired carbon dioxide (FECO2) every 15 seconds during 
exercise (ParvoMedics TrueOne 2400, Sandy, USA) from a mixing chamber, while minute 
ventilation (VE) was recorded every 15 seconds using a turbine ventilometer (Morgan, Model 096, 
Kent, England). The gas analysers were calibrated immediately prior to testing and verified after 
each test using a certified beta gas mixture (BOC, Brisbane, Australia). The ventilometer was 
calibrated before and verified after each test using a 3 L calibration syringe (Han Rudolph Inc., 
Kansas, USA) in accordance with the manufacturer’s instructions.  The test was terminated when 
the participant reached volitional fatigue or met exercise testing termination criteria as outlined by 
the American College of Sports Medicine (Appendix 5.3).  In circumstances where the test was 
terminated early, participants were required to recomplete the test within three (3) days. V̇O2peak 
was recorded as the average of the highest two V̇O2 readings recorded.  The testing protocol, 
modified from that of Balke and Ware[126], began with three minutes of rest for respiratory 
normalisation followed by four minutes of warm up at a resistance of 50 W.  Thereafter the 
resistance provided by the cycle ergometer increased incrementally by 25 W every minute.  
Participants were required to maintain a cycling cadence of above 50 revolutions per minute (rpm).  
HR was recorded every minute whilst BP was monitored every two minutes during the V̇O2peak 
test.  Participants were also asked each minute to indicate their rating of perceived exertion (RPE) 
on a Borg’s Scale[127]. Both HR and BP measures were monitored until they returned to within 10 
bpm and 10 mmHg of resting levels, respectively, before participants left the laboratory. 
Exercise Intervention 
Following baseline testing, individuals were randomised into one of two treatment arms using a 
random number generating process and stratified based on gender and age. An individual 
independent to the study was responsible for the randomisation of participants. All exercise training 
sessions were conducted on an air- and magnetically-braked cycle ergometer (Wattbike Ltd., 
Nottingham, England) at the Exercise Physiology Research Laboratory within the School of Human 
Movement Studies at The University of Queensland.  
 
Once baseline testing was complete and training groups established, participants started cycle 
ergometer training. Both groups completed 24 exercise sessions (3 sessions per week for eight 
weeks).  
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As described by Tjonna et al.[128], each HIIT training session involved 4 x 4 minute bouts of 
exercise at an intensity of 85-95% heart rate peak (HRpeak). Each 4 minute interval was separated by 
3 minutes of active recovery at 70% HRpeak. The HIIT sessions included a 10 minute warm-up and 5 
minute cool down at 70% HRpeak.   
 
Participants randomised to the MIT group exercised at 70% HRpeak for 50 minutes. The duration of 
50 minutes for the MIT group was chosen for two reasons.  Firstly, 3 x 50 minute session would 
meet the current physical activity guidelines as set by the American College of Sports Medicine for 
adults[129].  Additionally, data published by Tjønna! et! al.[128] estimated that 47 minutes of 
moderate intensity exercise was of equal workload to the previously described HIIT session in 
patients with metabolic syndrome, as determined by V̇O2.  Thus, 50 minutes of MIT was 
comparable to HIIT to the energy expenditure of the 4 x 4 minute HIIT session and met the current 
physical activity guidelines.    
 
Exercise training sessions were completed individually or in small groups (3-4 people) and 
supervised by an accredited exercise physiologist. HR was monitored continuously using a heart 
rate monitor (Suunto Oy, Vantaa, Finland). Examples of these HR graphs for HIIT and MIT 
sessions can be found in Appendix 5.7. RPE was monitored at the completion of each interval in the 
HIIT groups and at regular intervals (15 minutes) in the MIT group.  All participants had their BP 
and HR measured prior to commencement of each training session.  These measures needed to have 
returned to within 10 bpm and 10 mmHg of baseline measures, respectively, before participants left 
the facility. In the instance where a participant achieved a higher HRpeak at midpoint testing than the 
HRpeak recorded in their baseline testing, this new HRpeak was used to recalculate 85-95% HRpeak and 
70% HRpeak for exercise prescription of the HIT and MIT sessions, respectively.   
 
Attendance and Safety 
Attendance and safety was recorded in order to assess and describe the feasibility and 
appropriateness of high intensity exercise for CRC survivors.  Attendance at the exercise training 
sessions (out of a possible 24) was recorded whilst adverse events as a result of the exercise training 
were documented at the time of incidence by the Principal investigator.   
 
Statistical Analysis 
A sample size calculation indicated that to detect a 1.0 pg/mL difference in plasma IL-8 levels 
between time points, with a SD of 1.1 pg/mL[16], alpha=0.05 and power=80%, 16 participants (8 
per group) would be required to determine changes (G*Power Software, University of Düsseldorf, 
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Germany). A systematic review of exercise trials in cancer survivors found, on average, an 11.9% 
dropout rate[130]. Conservatively allowing for an anticipated dropout rate of 15%, a total sample 
size of 20 participants (10 per group) was targeted to exceed 80% power to detect a significant 
effect in IL-8 between time points. 
 
Data were analysed using the SPSS statistical software package (version 20.0, SPSS, Inc., Chicago, 
IL). Normality was assessed using the Shapiro-Wilk test. Outcome measures was analysed using 
standard descriptive statistics, t tests, Pearson’s correlation coefficients, and regression or the 
comparable non-parametric test as necessary to examine differences between time points. Potential 
effect modification of sex, age, baseline IL-8 levels, body composition, and fitness was also tested. 
Differences in secondary outcomes were evaluated using multi-level analyses.   
Analysis of lean mass was further broken down into segments (lower limbs, trunk, and lower limbs) 
in an attempt to identify the location of any changes or redistributions.  Given the non-specific 
nature of fat mass reduction it was not deemed appropriate to conduct such analysis in the presence 
of significant changes in fat mass. 
 
For all tests, an alpha level of 0.05 was applied as the criterion for statistical significance.   
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3.3 Results 
Baseline characteristics for participants in both training groups are shown in Table 3.  There was no 
significant difference between groups for any baseline measure with the exception of sex 
differences (p=0.004).  With the exception of baseline VO2peak in the MIT group, all baseline data 
were normally distributed. 
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Table 3: Baseline participant characteristics and between group comparisons 
 HIIT 
(n=9) 
MIT 
(n=9) 
p value 
Age (yrs)  60.9 ± 15.7 61.4 ± 11.2 0.932 
Sex [Men (n (%))] 8 (88.9) 3 (33.3)   0.004 # 
Body Composition    
Height (cm) 156.7 ± 7.4 168.3 ± 14.2 0.294 
Body Mass (kg) 80.0 ± 10.7 78.3 ± 20.7 0.202 
Fat Mass (kg) 29.07 ± 6.70 29.22 ± 10.14 0.971 
Lean Mass (kg) 51.39 ± 7.15 41.17 ± 14.40 0.075 
Body Fat (%) 35.0 ± 6.05 40.6 ± 6.78 0.085 
Cancer Site   0.303 
Colon 9 (100.0) 8 (88.9)  
Rectum 0 (0.0) 1 (11.1)  
Cancer Stage   0.493 
Stage [n (%)] 2 (22.2) 3 (33.3)  
Stage II [n (%)] 3 (33.3) 3 (33.3)  
Stage III [n (%)] 2 (22.2) 3 (33.3)  
Stage IV [n (%)] 2 (22.2) 0 (0)  
Treatment   0.842 
Sx [n (%)] 3 (33.3) 3 (33.3)  
Sx + Rx [n (%)] 0 (0) 0 (0)  
Sx + Cx [n (%)] 4 (44.4) 3 (33.3)  
Sx, Cx, + Rx [n (%)] 2 (22.2) 3 (33.3)  
Time Since Diagnosis (yrs) * 2.00 (2.88) 3.00 (7.38) 0.347 
Time Since Treatment (yrs) * 2.00 (2.75) 2.00 (4.38) 0.620 
Physical Activity Levels (Godin 
Score) * 
20.00 (17.50) 35.00 (31.50) 1.000 
V̇O2peak (mL.kg-1.min-1) * 21.1 (3.6) 20.5 (2.3) (n=7) 1.000 
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IL-8 (pg.mL-1) 5.2 ± 2.7 6.5 ± 3.0 0.362 
Values reported as means ± standard deviation unless otherwise indicated 
*values reported as medium (interquartile range). 
#P<0.05 between groups. 
HIIT: High intensity interval training; MIT: Moderate intensity training; V̇O2peak: peak volume of oxygen 
consumed; Sx: surgery; Rx: radiation; Cx: chemotherapy; Godin Score: Godin Leisure-Time Exercise Questionnaire 
Score; IL-8: Interlukin-8. 
 
It was intended that each participant attended four testing sessions and 24 training sessions, totalling 
72 testing and 432 training sessions across the intervention.  From the time of randomisation, 
attendance at testing and training sessions for the HIIT group were 100% (36 of 36) and 99.1% (214 
of 216 sessions) respectively whilst those in the MIT group attended 100% of testing (36 of 36) and 
training (216 of 216) sessions. Throughout the intervention there were no significant adverse events 
nor were hospital admissions, myocardial infarctions or deaths recorded.  One participant’s 
V̇O2peak test was terminated early due to systolic BP exceeding 250mmHg; the participant repeated 
the V̇O2peak test seven days later and data from the participant’s retest was included in the 
analyses. Some participants within the HIIT group experienced mild nausea and light-headedness 
following the final exercise interval during their first few sessions however this was infrequent and 
quickly dispelled during the warm down period.   
 
Adherence to the HIIT protocol was assessed by recording how long participants spent within their 
target HR range of 85-95% HRpeak during each interval.  These data are summarized in Table 4.  
Within the four minute high-intensity intervals, participants took an average of 38.6 s to reach their 
target HR zone and spent the remaining 03:21.36 min within this HR zone.  Participants in the HIIT 
group each spent 322:10.56 minutes exercising in their target HR zones across the whole 
intervention.  This is compared with the participants in the MIT group who completed a total of 
1200:00:00 minutes of moderate intensity exercise at a HR of 70% of HRpeak. 
 
Table 4:  Average adherence to High Intensity Interval Training protocol. 
 
 Interval 1 Interval 2 Interval 3 Interval 4 All Intervals 
Time to target 
HR (min:ss) 
01:05.62 ± 
00:51.35 
0:37.88 ± 
00:33.07 
00:29.33 ± 
00:28.59 
00:22.09 ± 
00:23.78 
00:38.64 ± 
00:39.27 
Time spent in 
target HR zone 
(min:ss) 
02:54.38 03:22.12 03:30.67 03:37.91 03:21.36 
Values expressed as average times ± standard deviation. 
HR: Heart Rate 
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As shown in Table 5, analysis of plasma samples revealed no significant difference in IL-8 
concentrations between groups at baseline (p=0.362).  Further, neither the HIIT nor MIT training 
protocol resulted in significant within-group differences in IL-8 at midpoint (p=0.803 and p=0.275 
respectively) or 8 week testing (p=0.980 and p=0.065 respectively).  A non-significant downward 
trend was seen within the MIT group between baseline and 8 weeks (p=0.065).  Similarly, when 
participants who were identified as having elevated baseline IL-8 concentrations were pooled (n=4), 
a trend towards a reduction in IL-8 was observed (p=0.068; Table 6).  Elevated baseline IL-8 
concentrations were defined as being greater than two standard deviations above the mean of 
apparently healthy individuals (4.39 ± 1.63 pg.mL-1)[131]. No between-group differences in IL-8 
were observed at midpoint (p=0.915) or 8 week testing (p=0.337). 
 
Table 5: Plasma IL-8 across the intervention. 
 
 
Baseline 
(pg.mL-1) 
4 Weeks 
(pg.mL-1) 
8 Weeks 
(pg.mL-1) 
HIIT 5.2 ± 2.7 5.5 ± 3.5 5.3 ± 2.7 
MIT 6.5 ± 3.0 5.4 ± 1.8 4.2 ± 1.5 
Values expressed as means ± SD. 
HIIT: High intensity interval training; MIT: Moderate intensity training. 
 
Table 6:  Plasma IL-8 concentrations in participants who had elevated levels at baseline. 
 
 
Baseline 
(pg.mL-1) 
4 Weeks 
(pg.mL-1) 
8 Weeks 
(pg.mL-1) 
Exercise Group 
(n=4) 
 (HIIT = 2; MIT = 2) 
9.8 ± 2.0 6.8 ± 3.1 5.6 ± 1.6 
Values expressed as means ± SD. 
 
V̇O2peak significantly increased in both groups in response to training (Table 7). The median 
V̇O2peak increases from baseline to 4 weeks in the HIIT and MIT groups were 6.06 (IQR: 6.97) 
mL.kg-1.min-1 (p=0.036) and 1.95 (IQR: 1.80) mL.kg-1.min-1 (p=0.043), respectively, however no 
difference between the groups was observed (p=0.315). When baseline V̇O2peak was compared to 8 
week testing, the median change in the HIIT group was 7.99 (IQR: 6.49) mL.kg-1.min-1 (p=0.015) 
and in the MIT group was 3.20 (IQR: 2.79) mL.kg-1.min-1 (p=0.018). 8 week V̇O2peak measures for 
HIIT and MIT groups were not significantly different to midpoint values (p=0.263 and p=0.071 
respectively). However, by 8 week testing, a significant group effect was observed with the HIIT 
group having a higher V̇O2peak than their MIT counterparts (p=0.041). 
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From baseline to 8 week testing, changes in body composition were observed in both groups; these 
are detailed in Table 7 and Figure 7.  At baseline, no significant differences were observed between 
the groups for any measure of body composition, despite lean mass (p=0.075) and body fat 
percentage (p=0.085) approaching significance.    
 
After four weeks of training, the HIIT group experienced significant reductions in fat mass (mean 
change = -1066.8±535.7 g; p=0.0003) and body fat percentage (mean change = -1.3±0.5%; 
p=4.1x10-5) as well as a significant increase in lean mass (mean change = 1123.7±570.8 g; 
p=0.0004).  In contrast, there were no significant changes from baseline to four week testing in 
body composition for the MIT group, though lean mass appeared to trend positively (mean change 
= 725.6±1041.8 g; p=0.070).  There was no significant difference in fat mass, lean mass, or body fat 
percentage between groups at four week testing (p=0.315, p=0.070, and p=0.166 respectively).  
However, when comparing the mean changes experienced by the groups, the reduction in fat mass 
was significantly greater in the HIIT group (p=0.046). 
 
Compared to baseline, significant changes in body composition were observed at endpoint testing in 
the HIIT group in fat mass (mean change = -1110.9±823.22 g; p=0.004), body fat percentage (mean 
change = -1.3±0.8%; p=0.0009) and lean mass (mean change = 983.4±663.4 g; p=0.002. Similar to 
midpoint testing, there were no significant differences from baseline to endpoint testing in any 
measure of body composition for the MIT group (p=0.235, p=0.139, and p=0.162 respectively).  
There was also no significant difference between midpoint and endpoint testing in any body 
composition measure for either group.  A between-group effect was seen in lean mass (p<0.003) at 
endpoint favouring the HIIT group.  A non-significant between-group effect was observed in body 
fat percentage at midpoint (p=0.074) and endpoint (p=0.055) suggesting the HIIT group 
experienced more favourable outcomes.  A group effect was also seen for fat mass when analysing 
the mean change where the HIIT group experienced significantly greater fat mass loss (p=0.017). 
 
Further analysis of segmental lean mass revealed significant changes in the HIIT group, as 
expressed in Table 8.  Lower limb segments exhibited significant increases in lean mass at midpoint 
and endpoint testing (p=0.020 and p=0.013 respectively) whilst a significant difference was found 
in the torso segment (p=0.042) at midpoint only.  No differences were observed in the MIT group. 
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Table 7: V̇O2peak and body composition measures for both groups across the intervention.   
 HIIT MIT 
 Baseline Four Weeks Eight Weeks Baseline Four Weeks Eight Weeks 
V̇O2peak (mL.kg-1.min-1) 
 
21.07 (3.60) 26.68 (9.88) a 26.99 (7.48) a * 20.48 (2.30) 21.09 (3.93) a 21.95 (3.34) a 
Fat Mass (kg) 29.07 ± 6.70 28.00 ± 6.94 a 27.96 ± 6.69 a 29.22 ± 10.14 28.82 ± 10.33 28.92 ± 10.50 
Lean mass (kg) 51.38 ± 7.15 52.51 ± 7.39 a 52.37 ± 7.39 a * 41.17 ± 14.40 41.90 ± 15.14 41.29 ± 13.13 
Body fat (%) 35.0 ± 6.05 33.7 ± 6.13 a 33.7 ± 6.24 a 40.6 ± 6.78 39.9 ± 7.58 40.0 ± 6.73 
Values reported as means ± SD unless otherwise denoted. V̇O2peak expressed as means (IQR) 
a=p<0.05 versus baseline; *p<0.05 compared to the MIT group 
HIIT: High intensity interval training; MIT: Moderate intensity training. 
 
Table 8: Changes in segmental lean mass in HIIT group across the intervention. 
 Baseline Four Weeks Eight Weeks 
Upper Limbs (kg) 6.27 ± 1.21 6.29 ± 1.10 6.22 ± 1.22 
Lower Limbs (kg) 17.34 ± 2.16 17.88 ± 2.09a 17.81 ± 2.01a 
Trunk (kg) 27.71 ± 4.24 28.29 ± 4.46a 28.18 ± 4.21a 
Values reported as means ± SD unless otherwise denoted.  
a=p<0.05 versus baseline; *p<0.05 compared to the MIT group 
HIIT: High intensity interval training 
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A correlation matrix showing associations between changes in IL-8, V̇O2peak, and body 
composition is shown in Table 9 and Table 10. At four-week the MIT group experienced a change 
in lean mass that was significantly correlated with changes in body fat percentage (negatively; 
p=0.022).  There were no significant correlations between IL-8, V̇O2peak, or body composition at 
eight-week testing (p>0.05). 
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Table 9: Four-week correlation matrix of physiological and anthropometric changes. 
 
 Δ V̇O2peak Δ Fat mass  Δ Lean Mass 
Δ Body 
Fat % 
HIIT 
Δ V̇O2peak #  -0.214 -0.119 -0.386 
Δ Fat mass    -0.169 0.901** 
Δ Lean Mass     -0.467 
Δ Body Fat %     
MIT 
Δ V̇O2peak #  -0.314 -0.086 0.086 
Δ Fat mass    -0.643 0.944** 
Δ Lean Mass     -0.780* 
Δ Body Fat %     
*p<0.05; **p<0.01 
# Spearman’s correlation used as data was not normally distributed 
HIIT: High Intensity Interval Training; MIT: Moderate Intensity training; 
 
 
Table 10: Eight-week Correlation matrix of physiological and anthropometric changes.  
 
 Δ V̇O2peak Δ Fat mass  
Δ Lean 
Mass 
Δ Body 
Fat % 
HIIT 
Δ V̇O2peak #  0.383 -0.133 -0.261 
Δ Fat mass    -0.305 0.224 
Δ Lean Mass     -0.109 
Δ Body Fat %     
MIT 
Δ V̇O2peak #  0.429 0.257 0.200 
Δ Fat mass    0.223 0.567 
Δ Lean Mass     -0.574 
Δ Body Fat %     
# Spearman’s correlation used as data was not normally distributed 
HIIT: High Intensity Interval Training; MIT: Moderate Intensity training; 
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3.4 Discussion 
The present study is the first of its kind to examine the influence of exercise training intensity on 
IL-8 in CRC survivors.  This study aimed to initiate the scientific discussion surrounding the 
mechanistic link between exercise training and reductions in CRC risk.  The isolation of such a 
lynchpin would enable guidelines surrounding exercise training to be tailored to best manipulate 
this variable.  Furthermore, it was of particular interest to identify how different exercise training 
intensities could influence maximal aerobic fitness and body composition given their intrinsic 
relationship with general and cancer-related health.    
 
It was hypothesised that exercise training would reduce circulating IL-8 and that the magnitude of 
reduction would be greater in response to HIIT than to MIT.  The secondary hypotheses of this 
thesis were that the HIIT group would experience the largest increases in V̇O2peak and muscle mass 
whilst the MIT group would experience greater reductions in fat mass.  
 
The primary finding from this study was that circulating levels of IL-8 did not change for either 
group in response to the training intervention.  The secondary findings of this study were that 
exercise significantly improved V̇O2peak and resulted in changes to body composition.  In 
agreement with our hypothesis, the HIIT group exhibited the greatest increases in V̇O2peak and 
muscle mass.  However, the HIIT group also experienced larger reductions in fat mass that the MIT 
group, contrary to our original hypothesis.  The MIT group experienced no significant change in 
body composition, further disagreeing with our secondary hypothesis. 
 
3.4.1 Interleukin-8 
No change in circulating IL-8 concentrations in response to either MIT or HIIT was observed in the 
present study. This finding was contrary to our hypothesis but likely explained by the baseline 
concentrations of IL-8.  At baseline, the resting levels of IL-8 were 5.2 pg.mL-1 and 6.5 pg.mL-1 for 
the HIIT and MIT groups respectively, which is comparable to reported plasma values of healthy 
adults when analysed in similar conditions (4.39 ± 1.63 pg.mL-1) [132].  This explains the lack of 
significant change in plasma IL-8 concentrations as without the presence of abnormal levels, the 
role for exercise to normalise concentrations of this cytokine becomes redundant.  The fact that the 
observed values were not significantly reduced suggests that exercise has a hormetic effect on 
circulating cytokines.  That is, elevated levels would be reduced while low concentrations would be 
increased towards the optimal level.  It was thus unlikely that the present training intervention, at 
either intensity, would result in significant changes to the normal baseline IL-8 values.   
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It was expected that CRC survivors would present with elevated IL-8 levels at baseline.  There is no 
current documentation of resting IL-8 levels in this population in the literature however it was 
anticipated that individuals who are at greater risk of CRC would be accompanied by a systemic 
elevation in IL-8.  Indeed, the median time since treatment for each group was two years, with no 
participant being more than five years removed from their last treatment. As such no participants 
were considered to be in remission and were all still at a significant risk of recurrence.  Furthermore 
previous research in other cancer survivors has found such an association between elevated IL-8 
concentrations and survivorship.   In individuals who had previously been treated for breast cancer, 
it was found that baseline IL-8 concentrations (10.26 ± 2.34 pg.mL-1) were markedly higher than 
those found in healthy populations[133]. Given that CRC has been associated with elevated IL-8 
levels similar to breast cancer, it was expected that CRC survivors would have higher than normal 
IL-8 levels[134].  
 
Pre-screening participants for IL-8 concentrations and employing an inclusion criterion to only 
accept participants with abnormally high levels would have allowed more meaningful investigation 
of how exercise can improve markers of CRC in CRC survivors.  Such a cut-off was not used for 
the present study due to the aforementioned expectation of participants having elevated circulating 
IL-8; however in any case funding restrictions would have not allowed such analysis.  It is strongly 
encouraged that any future studies investigating the hormetic role of exercise on biomarkers of any 
disease employ such pre-screening unless there is strong and consistent literature detailing baseline 
levels.   
 
Only one of the 18 participants in the current study presented with concentrations greater than those 
previously observed in apparently healthy individuals. The lack of elevated IL-8 concentrations 
observed in the overwhelming majority of CRC survivors brings into question the role of IL-8 as a 
predisposing factor to CRC development. It is well established that plasma IL-8 levels increases 
concomitantly with cancer stage but whether or not IL-8 is increased in those at risk of, but yet to 
develop, the disease is less understood [65, 66].  Potentially, IL-8 concentrations may only increase 
after the cancer has begun developing whereby CRC cells have the ability to constitutively produce 
IL-8, explaining the lack of elevation in the participants of the present study[3].  In such case it 
would appear IL-8 is not the chief predisposing factor to CRC development and research into 
alternative theories for why CRC survivors are at an increased risk of recurrence should be 
considered in the future.  Knowledge of the exact lynchpin behind CRC recurrence would allow the 
development of effective preventative therapies.   
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Regardless, IL-8 inarguably has a role in promoting cancer progression in CRC patients and thus 
manipulation of this variable is still of interest[66, 135]. The proposal that exercise has a role to 
play in such cytokine modulation should be examined in a future study where participants are only 
included if their baseline IL-8 levels are elevated. As an example, participants from the present 
study with IL-8 concentrations greater than two standard deviations above the reported mean of 
apparently healthy individuals were pooled and analysed(n=4)[132]. Nonparametric analysis of 
these data identified a reduction in IL-8 concentrations in response to training approaching 
significance (p=0.068).  Whilst this secondary analysis is by no means conclusive, it gives support 
for the notion that exercise has a role in normalising abnormal IL-8 levels and suggests future 
research is warranted. Similar non-significant reductions in IL-8 concentrations were also seen in 
the original MIT group (p=0.065), likely due to the marginally elevated baseline levels observed in 
this cohort.  
 
It is therefore important that despite the overall findings of the present study, IL-8 remains at the 
forefront of researchers’ minds when developing new therapeutic avenues or prescriptions. Indeed, 
given that there were no adverse events in the present study, an experiment conducted with the 
same or similar exercise prescription but with CRC patients (rather than survivors having finished 
treatment for the disease) is suggested for future researchers.  This would assist in determining how 
well exercise can normalise elevated levels of IL-8 and what intensity of aerobic exercise is most 
effective. If exercise prescription could be optimised to best manipulate IL-8 in CRC patients, this 
may prove to be a very beneficial adjuvant therapy treatment plan.  
 
3.4.2 V̇O2peak 
A secondary outcome measure of this study was V̇O2peak, which significantly improved in both 
groups at midpoint and endpoint testing.  A group effect was also seen by endpoint testing, 
indicating that HIIT was more beneficial than MIT for improving V̇O2peak.   
 
Increases in V̇O2peak are clinically very important.  It is well established that maximal aerobic 
capacity (e.g. V̇O2peak) is an independent predictor of all-cause mortality[136].  For men, it has 
been suggested that for every increase in aerobic fitness of 1 MET, the risk of all-cause and 
cardiovascular disease mortality will reduce by 15% and 19%, respectively[46].  Similar 
associations between aerobic fitness and mortality have been observed in women, with an estimated 
risk reduction of 8% and 21% for all-cause and cardiovascular disease mortality, respectively[47, 
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137]. Reducing mortality risk by improving aerobic fitness is important for cancer survivors, as 
many have severely reduced levels of fitness following various treatment regimes[138].  
Furthermore, every 1 MET increase in fitness has been shown to reduce cancer-specific mortality 
by 5%, however this trend was non-significant (p=0.10)[139]. The ability to reduce risk of mortality 
from a variety of disease by improving aerobic fitness outlines the importance of exercise training 
following cancer treatment. 
 
Table 11 shows how the observed improvements in cardiovascular fitness over eight weeks of 
training in the current study may translate to reductions in mortality based on previously published 
literature[46, 139, 140].  Median increases in aerobic fitness of the HIIT and MIT groups can be 
expressed as 2.82 and 0.91 METs, respectively (1 MET = 3.5 mL.kg-1.min-1).   
Table 11.  Estimated reduction in risk of mortality. 
 HIIT MIT 
All-cause 42.3% 13.7% 
Cancer-specific 14.1% 4.6% 
CVD 53.6% 17.4% 
CVD=cardiovascular disease. 
 
With regard to the time-course of changes, most of the improvements in V̇O2peak observed in the 
present study occurred within the first four weeks (i.e., after only 12 training sessions).  The 
effectiveness of the intervention is further highlighted by considering that the HIIT group only 
spent 114 minutes exercising each week including warm ups and cool downs.  This is considerably 
less than the currently recommended 150 minutes per week of MIT proposed as the minimum 
duration necessary to gain health benefits[141].  It should be noted however that the minimum of 
150 minutes per week may be required for other health benefits and that the present findings only 
give suggestion that cardiovascular fitness improvements can be attained with less exercise of a 
higher intensity.  
 
Differences in absolute changes of V̇O2peak in response to training at different exercise intensities 
has been well documented in clinical populations[48].  Indeed, the present data are in agreement 
with previous findings and strongly supports HIIT to be more effective than MIT over relatively 
brief periods[48].  The present study stands out from previous exercise physiology research in CRC 
survivors when examining the time-course and magnitude of changes of V̇O2peak.  The absolute 
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and percentage change increases in V̇O2peak for the present HIIT group (8.0 mL.kg-1.min-1 and 
44.2%, respectively) are far greater than those reported in previous CRC research – the two studies 
presently reporting such data include increases in V̇O2peak of 3.0 (95% CI = 1.4 – 4.6) mL.kg-
1.min-1 following 12 weeks of combined aerobic and resistance training and 4.68 mL.kg-1.min-1 
following three months of a home-based physical activity intervention [18, 39]. Of these, Sellar et 
al.[18] measured V̇O2peak whilst Pinto et al.[39] only estimated V̇O2peak using submaximal 
testing. The study conducted Sellar and colleagues[18] comprised 12-weeks of combined aerobic 
(thrice weekly) and resistance exercise (twice weekly).  The aerobic component required 
participants to cycle on an ergometer at a moderate intensity for the first four weeks.  Through 
weeks five and six participants completed one session of HIIT and two sessions of moderate 
intensity exercise on the cycle ergometer.  Thereafter two sessions per week constituted HIIT with 
the remaining session being of moderate intensity.  All sessions were supervised by the research 
team with the HIIT sessions being comprised of long and short intervals as described by Guiraud et 
al.[142]. Despite this highly controlled and well-prescribed intervention, the ‘4x4’ protocol utilised 
in the present study yielded far greater improvements in V̇O2peak than those reported by Sellar et 
al.[18].  Indeed, following 12 weeks of exercise training, Sellar et al. reported a mean increase in 
V̇O2peak of 3.0 (95% CI = 1.4 – 4.6) mL.kg-1.min-1 compared to 8.0 (IQR=6.5) mL.kg-1.min-1 
observed in the present study across just 8 weeks. Moreover, greater increases in V̇O2peak were 
recorded in the first four weeks of the present study (6.1 (IQR=7.0) mL.kg-1.min-1) than were found 
across the entire 12-week intervention conducted by Sellar et al.[18].  A summary comparison of 
the two studies can be found in tabulated form in Appendix 5.8.  For the present study to have 
elicited greater benefits despite only being one third of the intervention duration of the study by 
Sellar et al.[18] highlights the exceptional efficacy of the ‘4x4’ HIIT protocol.  Given the marked 
variation in results between the current study and that of Sellar et al.[18], it is most logical to 
deduce that the intensity of exercise completed by the participants of the ‘4x4’ was significantly 
higher.  This cannot be conclusively stated however, as exercise prescription for the Sellar et al.[18] 
study was done so as a percentage of peak power output, thus restricting the ability to conduct 
straight comparisons. It should also be noted that participants in the previous study were 
concurrently completing regular resistance training[18].  Whether the adaptive processes of the two 
systems combatted each other somewhat thus damping aerobic improvements or perhaps 
participants were simply less capable of completing HIIT at such an intensity due to fatigue, further 
research is required to conclusively determine the optimal training regime for this population. 
 
The discrepancy between the HIIT and MIT groups in the present study favouring the former is 
consistent with previous research comparing exercise intensities in untrained populations[48, 143, 
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144].  It has been established that HIIT can elicit such benefits through a myriad of physiological 
processes, predominantly improvements in mitochondrial enzyme activity, increases in 
mitochondrial size, and greater rates of mitochondrial biogenesis[144].  By way of increasing the 
stress placed upon the muscle cells during exercise, HIIT can provoke a greater magnitude of these 
adaptive responses[144]. 
3.4.3 Body Composition 
Changes in body composition (reduced fat mass, increased lean mass, and reduced body fat 
percentage) were observed for the HIIT group but not for the MIT group in response to training.  
The significant improvement from baseline in body composition in the HIIT group were present at 
both midpoint and endpoint testing, with no further improvements from week four to week eight.    
 
The two studies that have previously assessed fat mass, muscle mass and/or body fat percentage in 
response to an exercise intervention in CRC survivors did not report any significant changes [18, 
75].  Differences in findings between the present study and those of Lee et al. and Seller et al. may 
relate to the exercise training protocols used as neither employed HIIT[18, 75].  The study 
conducted by Lee et al.[75] involved aerobic exercise at a significantly lower intensity than that 
used in the present study and was largely a home-based intervention.  The intervention conducted 
by Sellar et al.[18], previously detailed in Section 3.4.2, included both aerobic and resistance 
exercise. In the latter weeks of the Sellar et al. study, the aerobic exercise sessions began to include 
interval training, however there is little evidence to suggest that participants in this study were 
exercising at the same relative intensities as those in the present HIIT group. 
 
This suspected discrepancy in intensity is again the likely mechanism explaining the difference in 
findings of the present study.  It has been found that completion of a HIIT program can lead to a 
reduction in dependence on glucose utilisation and an increase in fat oxidisation in untrained 
individuals[145, 146].  In fact, such metabolic changes have been observed following only two 
weeks of HIIT.  This would mean the participants in the HIIT group of the present study completed 
the final six weeks of training with a vastly different balance of energy utilisation, thus promoting 
reductions in fat mass and body fat percentage. 
 
Whilst not as strongly linked with health outcomes as aerobic fitness, body composition is 
nonetheless related[51].  Historically, a 5% reduction in body mass was considered to be clinically 
significant, however this does not account for the various types of body tissue that make up body 
mass[147].  In more recent times, with the enhanced capacity to differentiate between lean mass and 
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fat mass, fat mass and body fat percentage have been positively associated with CVD and cancer 
risk[50, 51].  Lean mass has also been associated with a reduction in all-mortality risk, whilst the 
relationship between fat parameters and mortality is less conclusive given the protective effect fat 
mass can have in later life[148].  It is reasonable to conclude that the changes in body composition 
observed in the present study were favourable for health. 
 
It is important to acknowledge how efficient the HIIT training program was in eliciting changes in 
fat mass.  Whilst the HIIT group only experienced a moderate reduction in fat mass (1.1 ± 0.8 kg on 
average), the amount of exercise required to achieve this was well below the current guidelines for 
fat mass loss.  It is currently recommended by the American College of Sports Medicine that to 
achieve sustained weight loss, one needs to complete a minimum of 250 minutes of moderate 
aerobic exercise per week[52].  In this study however, participants in the HIIT group were only 
performing 114 minutes of aerobic exercise per week including warm up, recovery intervals, and 
warm down.   It cannot be concluded, however, from this study whether this acute weight loss 
would result in sustained weight loss, nor whether it is clinically significant.  This raises an 
important future research question to determine whether HIIT alone can elicit weight loss of such 
character or if such training protocols should be used to complement the current recommendations 
of MIT.   
 
Another important change relating to body composition was the increase in lean mass for the HIIT 
group.  These participants were cycling against greater resistance than those in the MIT group and 
this appears to have resulted in skeletal muscle hypertrophy as indicated by the increases in 
segmental lean mass in the lower limbs and trunk.    The increases in trunk lean mass may not seem 
commonsensical in response to cycling, an exercise modality almost solely of the lower limbs, until 
it is recognised that the DEXA analysis software includes the pelvis, and thus gluteal muscles, as a 
part of the trunk.  It is very conceivable that cycling would induce hypertrophy in such muscles in 
addition to those of the lower limbs.   
 
Further group-effect analysis was conducted on the absolute change values revealing the HIIT 
group experienced a reduction in fat mass of a significantly greater magnitude than the MIT group 
at both midpoint and endpoint.  Such a discrepancy is contrary to the traditional school of thought 
that MIT is more beneficial for weight loss than HIIT, as is outlined in the current American 
College of Sports Medicine Position Stand on exercise prescription for weight loss[52].  This 
consensus was brought about due to fat oxidisation being at its maximal rate when exercising at 
approximately 65% V̇O2peak with a marked drop off at intensities above 90% V̇O2peak[53].  
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However, a more recent review has outlined the potential for HIIT to elicit greater reduction in fat 
mass than MIT[149].  Given the absolute energy expenditure of HIIT is vastly greater than MIT, the 
deficit in fat oxidisation rates can be annulled.  Furthermore, as previously discussed, implementing 
a HIIT program in previously untrained individuals will lead to increases in fat oxidisation at higher 
intensities of exercise[146].  The present study supports this notion and extends this field of the 
literature by being the first to document the phenomenon in cancer survivors.  It should be noted, 
however, that MIT may be more appropriate for long-term, sustained weight loss which this study 
was not designed to evaluate[150].  To accurately evaluate whether HIIT or MIT is more effective 
in reducing fat mass, future studies need to be conducted over a greater time course and should be 
performed in conjunction with tight dietary control. 
 
The present data show that HIIT can produce significant changes in body composition very rapidly, 
i.e. within the first four weeks then plateauing.  The reasoning behind this plateau is not entirely 
clear but alternative approaches (e.g., dietary modification and resistance training) to continue 
improvements in body composition beyond 4 weeks may be required [151, 152].  The plateau 
observed in a number of variables after 4 weeks of training in the HIIT group may reflect over-
training.  Anecdotally, some participants were expressing minor signs of fatigue nearing the end of 
the intervention.  This is also supported by the lack of significant improvement in V̇O2peak between 
midpoint and endpoint.  To accurately identify whether either of these theories are indeed the case a 
longer-term intervention would need to be conducted with greater reporting of psychosocial 
parameters.  A further, avenue would be to then develop strategies to avoid this burnout effect.  
Potentially, an exercise program with shorter blocks of HIIT (for example of four weeks in 
duration) that is interspersed with less intense exercise, or even rest, may effectively combat this 
problem.     
 
3.4.4 Safety and Adherence 
There were no adverse events in in either training group in response to the present training 
intervention, therefore this study provides evidence to suggest that supervised HIIT and MIT are 
safe for CRC survivors.  Specifically regarding the HIIT group, the current study, of 297 training 
hours, mirrors previous research in clinical populations utilising the ‘4x4’ HIIT protocol, with zero 
adverse events reported[153].    
 
Strangely, the comparison of safety between HIIT and MIT is not something that has been well 
documented in the exercise physiology literature.   There is a theoretical acceptance that the HIIT 
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could elicit more adverse events due to the higher intensity inherent to the training regime as well as 
transient immune suppression following high intensity exercise.  The available literature, however, 
does not appear to support this with numerous HIIT protocols eliciting no adverse events in various 
clinical populations[18, 153-157] 
 
The described safety of this study is most attributable to the stringent screening and safety 
procedures employed.  As this was a pioneering study in utilising the ‘4x4’ HIIT protocol in CRC 
survivors, those with comorbidities or complications deemed possible to limit or prevent 
participation in the program were excluded.  Whilst this is a clear limitation of the study – the 
inability to generalise safety statistics to persons with comorbidities as regularly found in the 
general population – such a study design is a requirement of early stage research to strongly 
describe the basic physiological mechanisms at play and how they impact on health and fitness 
parameters within this sample population.  As such, this greatly reduced the risk of adverse events 
during training and testing.  It is therefore suggested that future research begin to include CRC 
survivors who are experiencing comorbidities such as diabetes, cardiac abnormalities, or 
musculoskeletal problems with an adapted training protocol as is necessary.   For the meantime, it is 
recommended that for patients whom could be classified in numerous clinical categories, HIIT be 
undertaken with consideration for the evidence base of both groups. 
 
Furthermore, for the sample populations, regular safety measures were put in place to prevent any 
adverse events.  Upon presentation to all testing and training sessions resting HR and resting BP 
were assessed and participation in the session was not initiated unless these values were permissible 
according to the American College of Sports Medicine’s Guidelines for Exercise Testing and 
Prescription[158].  A subjective assessment of general wellness was also conducted each session.  
Throughout the testing sessions HR, BP, and RPE were regularly measured whilst HR and RPE 
were measured throughout training sessions.  In the instance where BP was abnormal at rest 
(though not contraindicative of exercise), numerous exercising BP measurements were taken 
throughout the training session to monitor the response to exercise.  Lastly, participants were not 
permitted to leave the facility until resting parameters were representative of their pre-exercising 
values ensuring participants were adequately recovered.  It is thus recommended that similarly strict 
supervision be carried out whenever CRC survivors are completing HIIT in both the research and 
clinical setting in order to prevent adverse events.   
 
Previous clinical research has found great discrepancies in attendance rates to exercise interventions 
of both high and moderate intensities (range of 82-100% and 80-100% respectively).  The present 
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study experienced very high adherence (HIIT = 99.1%; MIT = 100%)[155, 156, 159], further 
suggesting HIIT to be a suitable form of exercise for this population.  As to why the recorded 
attendance of the current intervention was at the higher end of the previously seen ranges could be 
due to a number of factors.  The participants were recruited on a volitional basis meaning those who 
partook in the study had an inherent will to complete the program.  Furthermore, training sessions 
were commonly conducted in small groups with numerous supervising researchers.  As such 
participants were given almost one-on-one attention from supervisors whilst also being able to 
develop relationships and support networks with fellow participants.  This combination of 
interaction appeared to be very effective in building rapport and enjoyment at the anecdotal level.  
Further research could be conducted in a similar study to assess how different participant-supervisor 
dynamics affects adherence and ultimately biophysical outcomes.   
 
The present study goes beyond those existing in the literature by documenting how well participants 
adhered to their target HR zones during the high intensity intervals.  This is very surprising 
omission from previous research as differences in this parameter could largely alter a study’s or 
participant’s results.  Given that this has not been explored in previous research, the findings of this 
study cannot be compared to the data from other groups.  However, it is interesting to note that 
performing only four bouts of high intensity exercise lasting on average 3:21 minutes each is 
enough to elicit such significant changes in body composition and fitness of CRC survivors.  This 
highlights the exceptional efficiency of HIIT. 
 
3.4.5 Limitations and Future Directions  
The greatest limitation of the present trial was the lack of pre-screening for elevated IL-8 levels in 
participants recruited for the research.  As explained earlier, it was expected that the recruited 
participants would present with elevated levels, however time and financial constraints meant that 
pre-screening would not have been viable in any case.  In the absence of existing data on the 
concentrations of IL-8 in CRC survivors, this expectation stemmed from previous research in breast 
cancer survivors who clearly demonstrated elevated IL-8 concentrations[133].  It was the belief of 
the authors that CRC survivors would demonstrate exhibit, if not higher, concentrations of IL-8 
given the fact IL-8 plays a more important role in CRC than breast cancer[134].  Going forward, the 
present study has shown that CRC survivors are not exposed to higher levels of circulating IL-8,.  
Therefore, as previously discussed, the role of IL-8 in survivors also must be questioned and it may 
be worthwhile for future studies to investigate other potential markers. 
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Additional control measures regarding parameters such as time since diagnosis, time since 
treatment, treatment type, cancer site, and cancer stage would also allow more specific 
understanding.  Alternatively, a greater sample size would allow for subcategories to be formed 
within the data set based on these parameters and allow comparative analysis.  Similarly, the 
unequal distribution of sex between the two groups, despite using this as a randomising variable, is 
an unfortunate occurrence and with a greater sample size such a discrepancy would have likely been 
eliminated. It also may be advisable for future research to stratify participants based on previous PA 
levels as well as age and gender.  Although this study detected no significant difference between PA 
levels at baseline, the Godin Leisure-Time Activity Questionnaire does not specifically determine 
whether participants previously engaged in HIIT, potentially influencing the findings.  While it is 
possible that participants may have been already engaging in high intensity exercise, all available 
evidence relating to activity levels of cancer survivors, including the large improvements in 
physiological measures following the present intervention, suggests that this was highly unlikely. 
Indeed, recently published data [160] suggests that only 12.3% of prostate cancer survivors in 
Australia are meeting current physical activity guidelines and it is reasonable to assume that CRC 
survivors from the same geographical location would be of a similar standing.  
 
As it has now been established that HIIT is a very effective means of exercise training for this 
populations, an effort should be made to assess how well CRC survivors tolerate HIIT.  Conducting 
a similar study with the inclusion of psychosocial measures such as Functional Assessment of 
Chronic Illness Therapy and Functional Assessment of Cancer Therapy questionnaires would allow 
such evaluation.  Further to this point, training programs that integrate both MIT and HIIT to 
prevent burnout are suggested.   
 
Likewise, assessing the viability of HIIT in CRC survivors with comorbidities that were used as 
exclusion criteria for the present study is recommended, as indicated in the previous section.  
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4.0 Conclusion  
The present investigation has shown that IL-8 concentrations in CRC survivors did not change in 
response to 8 weeks of HIIT and MIT.  This may have been related to the normal baseline 
concentrations of IL-8 in all but four of the study’s participants.  When those four, who had higher 
than normal resting IL-8 concentrations, were examined there was a trend towards lower levels as a 
result of the training intervention.    
 
The HIIT intervention did, however, succeed in positively altering body composition in this 
population.  Significant improvements in maximal aerobic capacity were observed in both groups 
however much more pronounced for those completing HIIT.  Indeed, changes in maximal aerobic 
capacity and body composition were present within only 4 weeks of HIIT. 
 
The study has furthered the current research bed demonstrating the effectiveness and, most 
importantly, the safety of the ‘4x4’ HIIT protocol in clinical populations. HIIT in this form and 
setting proved to be a feasible and suitable method of exercise for CRC survivors.  
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Abstract 
Physical activity (PA) is related to colorectal cancer (CRC) mortality, with approximately 15% of 
CRC deaths worldwide attributable to physical inactivity. Moreover, higher levels of PA in CRC 
survivors have been associated with a reduced risk of the disease recurring. Despite the recognised 
nexus between PA and the risk of CRC, the physiological mechanisms underlying the inverse 
relationship between PA and mortality following CRC diagnosis are less apparent, with evidence 
primarily drawn from epidemiological studies. The insulin-like growth factor (IGF) axis plays a 
central role in cellular growth, proliferation regulation, differentiation and apoptosis. Specifically, 
high levels of insulin-like growth factor 1 (IGF-1) have been consistently linked to the severity of 
CRC tumours. Further, insulin-like growth factor binding protein 3 (IGFBP-3) regulates the 
bioavailability of IGF-I and therefore plays a central role in CRC prognosis. Decreasing levels of 
IGF-1 and increasing levels of IGFBP-3 may thus be a plausible mechanism underlying the inverse 
association between PA and CRC survival.  
 
Introduction 
Of all cancers, colorectal cancer (CRC) has the fourth highest incidence rate worldwide and it is 
estimated that CRC is responsible for the deaths of approximately 608,000 people each year [1]. 
Given these statistics, reducing CRC incidence, recurrence and improving survival have emerged as 
major public health priorities.  
 
Physical activity (PA) has been specifically linked to CRC mortality, with approximately 15% of 
CRC deaths worldwide being attributable to physical inactivity [2] Further, epidemiological data 
show a significant decrease in disease-specific mortality for individuals who are physically active 
after diagnosis compared to those who are not [3,4].  However beyond recognising a relationship 
between PA and CRC survival, the biological mechanisms that underpin this association are not 
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entirely clear. Given that the insulin-like growth factor (IGF) axis has been implicated as a key host 
pathway responsible for the association between PA and CRC specific mortality [5-7],  using PA to 
influence the IGF axis may represent an effective means of reducing CRC mortality and improving 
survival. This paper will review the available evidence relating to PA following CRC diagnosis, the 
IGF axis and survival from the disease. 
 
1.0 Physical Activity and Colorectal Cancer  
An inverse relationship between PA and the incidence of CRC has consistently been reported in the 
literature [8-10]. Furthermore, engaging in PA after CRC diagnosis is associated with 50-60% 
reductions in disease-specific mortality [11-14]. Despite the important role PA has for the health of 
survivors following CRC diagnosis, specific PA guidelines for reducing the risk of CRC-related 
mortality following diagnosis do not yet exist.  
 
1.1 Physical Activity and Colorectal Cancer Incidence 
Over the past ten years, three meta-analyses [8,9,15] have reported an inverse relationship between 
PA and the incidence of colon cancer. Samad et al. [8] analysed nineteen cohort and twenty-eight 
case-control studies and identified a relative risk (RR) for developing colon cancer of 0.79 when 
comparing the leisure-time PA of the most to the least active men. For women, a RR of 0.71 was 
identified for recreational PA when comparing the most active to least active [8]. More recently, 
Wolin et al. [9] found a RR of 0.76 for both men and women when comparing the most to the least 
physically-active individuals. Further, Boyle et al. [10]  highlighted an inverse dose-response 
relationship between PA and colon cancer risk in eleven of the twenty-one studies included in their 
analysis.  
 
Whilst these results offer support for the promotion of PA to reduce the risk of colon cancer, there 
is little evidence that PA can decrease the risk of developing rectal cancer [8,9,15]. The reason for 
this disparity is unknown. The closest understanding to the relationship between PA and rectal 
cancer is derived from studies that demarcate the colon into proximal and distal sub-sites during 
statistical analysis. However, findings from these studies offer no significant differences between 
proximal and distal colon regions with a RR of 0.73 and 0.74, respectively, when comparing the 
most to the least physically-active individuals [10]. A greater understanding of the physiological 
link between PA and colon cancer from a survival perspective may explain why rectal cancer 
incidence does not appear to be mediated by PA.  
 
1.2 Physical Activity and Colorectal Cancer Survivorship 
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Following conventional treatment, CRC survivors who remain or become physically active have a > 
50% reduction in cancer-specific mortality over those who are inactive [11-13]. Indeed, researchers 
recommend exercise as an adjuvant to conventional treatment for those diagnosed with the disease 
[8,9,11-15].  
 
Meyerhardt et al. [11] found an inverse relationship between PA and hazard ratio for CRC-specific 
mortality in male survivors. In a cohort of 661 men, those who engaged in more than 27 metabolic 
equivalent of task (MET) hours of PA per week had a CRC specific mortality hazard ratio of 0.47 
compared to those who engaged in less than 3 MET-hours per week [11]. In a cohort of 573 female 
CRC survivors, a RR of 0.39 was found for those who engaged in at least 18 MET-hours of PA per 
week compared to those who engaged in less than 3 MET-hours per week [12]. Both studies found 
no change in statistical significance following adjustment for cancer stage (I-III), body mass index 
(BMI) and pre-diagnosis levels of PA. Such evidence highlights the importance of PA following 
diagnosis irrespective of pre-diagnosis activity levels. Although the specific frequency, intensity, 
type and mode of PA required for reductions in CRC specific mortality is uncertain, Meyerhardt et 
al. [11] have indicated that a protective effect for this measure occurs at approximately 9 MET-
hours per week. This volume of PA aligns well with the current adult PA guidelines for health 
benefits [16].   
 
The majority of studies that have investigated the relationship between PA and CRC survival have 
not reported the frequency, intensity, duration and/or mode of activity of the participants [8,9,11-
15]. To a large part, this can be attributed to the limitations of self-report PA measures used in these 
studies, which typically estimate activity levels using MET values. It has been shown that 
participants tend to over-report than under-report PA when recalling previous activity levels [17]. 
This limits the conclusions that can be drawn from studies with respect to the ’dose’ of PA required 
to elicit a protective effect. Research that involves structured PA interventions is required to better 
understand the relationships between CRC survival and PA that have been identified in prospective, 
case-control studies. Results from these intervention trials will help to determine the optimal ‘dose’ 
of exercise required to reduce CRC incidence and disease-specific mortality post-diagnosis. The 
Colon Health and Life-Long Exercise Change trial (CHALLENGE) [18] aims to address this 
limitation; this ongoing randomised controlled trial incorporates a multicentre PA intervention 
utilising instrumented measures of PA and aerobic fitness for people with stage II and III colon 
cancer. The primary outcome of this trial is disease-free survival, with cardiovascular fitness a 
secondary endpoint. This study will also track key biological markers believed to underpin the 
relationship between PA and colon cancer risk.  
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2.0 Insulin-like Growth Factors and Colorectal Cancer 
Changes in gastrointestinal transit time, inflammation, immune function, genetic mutations, insulin 
and the IGF axis have all been suggested as mediators to explain the relationship between PA and 
CRC incidence and disease-specific mortality [19,20]. Specifically, it is believed that the IGF axis 
plays a central role in cellular growth, proliferation regulation, differentiation and apoptosis [21,22]. 
Given these mechanisms, IGFs and their binding proteins (IGFBPs) have been identified as a key 
research focus in CRC pathology [23].  
 
The IGF axis has been linked to the primary and secondary development of CRC in meta-analyses 
of prospective studies [7,24]. Cross-sectional research has also found associations between the IGF 
axis and the graded severity of CRC carcinomas [23,25,26]. Manipulation of the IGF axis through 
PA may therefore be a promising therapy for preventing CRC, as well as reducing the likelihood of 
CRC-specific mortality post-diagnosis. 
 
2.1 Insulin-like Growth Factor Axis  
The IGF axis consists of two polypeptide ligands (IGF-I and IGF-II), two cellular membrane 
receptors (IGF-IR and IGF-IIR), and six binding proteins (IGFBP-1 through IGFBP-6). IGF-I and 
IGF-II are produced via the endocrine, paracrine and autocrine systems [27]. Growth hormone (GH) 
plays a dominant role in the upregulation of IGF-I with serum levels peaking around puberty and 
then decreasing throughout life [28,29]. IGF-I levels are also influenced by sex and nutritional 
status with higher levels found in females [30], periods of excess energy intake [31] and obesity 
[28]. Unlike IGF-I, the release of IGF-II is GH independent and levels remain stable after puberty 
[27]. At a cellular level, IGF-I and IGF-II accelerate cell cycle progression through the growth 
phase where DNA replication occurs [32]. Analogous to this growth-facilitating effect, IGF-I and 
IGF-II have the capacity to block cellular apoptosis. These processes have been reported in healthy 
[33] and malignant tissue [34], highlighting the potential role of IGF-I and IGF-II in the progression 
of CRC following diagnosis. 
 
The biological actions of IGF-I and IGF-II are mediated via two cell-surface receptors; IGF-IR and 
IGF-IIR [33]. Because of the structural similarities between IGF-I and IGF-II, the IGF-IR is able to 
bind both molecules albeit at different affinities. IGF-IR favours IGF-I, binding the molecule at a 2-
15 fold higher affinity than IGF-II [35]. Unlike the IGF-IR, the IGF-IIR does not bind IGF-I; this 
receptor specifically binds IGF-II, and at a 500-fold affinity greater than the IGF-IR [22]. Because 
binding of IGF-II to the IGF-IIR results in degradation of the molecule, the intra-cellular actions of 
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IGF-II are thought to be primarily mediated through the IGF-IR [36]. This complex association 
underpins the uncertainty that exists for the role of the IGF axis within the relationship between PA 
and CRC.  
 
The majority (~75%) of IGF-I and IGF-II produced via the endocrine system are bound in a ternary 
complex with IGFBPs and an acid labile subunit (ALS) [37]. The remaining IGF-I and IGF-II 
circulates in free form or in a binary unit with IGFBPs only [37].  Because ALS only has an affinity 
for IGF-I/IGF-II that is bound in a IGFBP complex, IGFBPs are thought to control the 
bioavailability of IGF-I and IGF-II [38]. This is actioned via three distinct pathways; 1) 
transportation, 2) prolonging the half-life of IGFs and protecting them from degradation, and 3) 
modulating the interaction between IGFs and their receptors [39]. When combined in the ternary 
unit, IGF-I and IGF-II are unable to bind to the cell surface receptors, IGF-IR and IGF-IIR. This is 
due to the up to 50 fold higher affinity of IGFBPs for IGF-I and IGF-II over their respective 
receptors [39]. The outcome of this affinity is thought to be the inhibition of IGF receptor 
activation, which in turn prevents IGF-I and IGF-II mediated cellular proliferation and reduces anti-
apoptosis. In contrast, IGFBPs prolong the half-life of IGF-I and IGF-II via the prevention of 
proteolytic degradation that would normally occur if IGF-I and IGF-II were circulating in isolation 
[37]. This results in a lengthening of IGF-I and IGF-II bioavailability [40]. Given these differing 
processes, IGFBPs can facilitate or inhibit the mitogenic actions of IGF-I and IGF-II. These 
mechanisms indicate that IGFBPs may be of equal importance to IGF-I and IGF-II in mediating 
cellular growth and understanding how PA influences CRC incidence and mortality.  
 
In serum, IGFBP-3 is the most abundant IGF binding protein, carrying approximately 90% of all 
bound and free circulating IGF-I and IGF-II [6]. Independent to its association with IGF-I and IGF-
II, IGFBP-3 has been found to have a pro-apoptotic and anti-proliferative capacity [41]. This has 
led to a focus on this specific binding protein as a mediator for the development and progression of 
colorectal neoplasms.  
 
A limitation to the measurement of these biomarkers in existing cancer research is that they may not 
reflect downstream cellular growth. Assays used to measure IGF-I and IGF-II do not discriminate 
between free form IGF-I/IGF-II, and that which is bound in binary and ternary units [38]. Because 
of this, current techniques may not reflect the bioactive IGF-I and IGF-II that are able to interact 
with cellular receptors. Furthermore, given that IGFBPs have both growth facilitating and inhibiting 
effects, direct measures of these biomarkers cannot accurately predict pro- or anti-proliferative 
processes. An assay that overcomes these limitations will enhance the understanding of how 
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exercise influences the IGF axis interaction with carcinomas. Identifying the action of intracellular 
growth processes rather than merely measuring circulating levels of these biomarkers is needed. 
Nonetheless, reductions in plasma IGF-I and IGF-II, and increases in IGFBP-3 suggest a more 
favourable outcome for the prevention of CRC and reductions in disease-specific mortality. 
 
2.2 Insulin-like Growth Factors and Colorectal Cancer Survival 
There is strong epidemiological evidence linking IGF-I, IGF-II and IGFBP-3 to the primary 
development of CRC [7,24,42-45]. What is less apparent is the nexus between the IGF axis and the 
development of secondary tumours. Although 5-year relative survival for localised CRC is 
promising (89.9%), those who experience secondary and tertiary tumours following diagnosis have 
a poorer prognosis, with expected survival rates of 69.6% and 11.9%, respectively [46].  
 
Research has identified significant associations between tumour severity and IGF-I, IGF-II and 
IGFBP-3 [23,25,26,47,48]. These studies have focussed on tumour grade and metastasis, where a 
greater tumour grade and extent of metastasis infers a heightened CRC-specific mortality risk 
[23,25,26,47,48].  In an animal model, IGF-I has been found to influence colon cancer tumour 
growth and metastasis in liver-IGF-I deficient (LID) mice, which have approximately 75% less 
endogenous IGF-I than controls [47].  Following transplantation of colon adenocarcinomas, LID 
mice had smaller and fewer tumours with less liver metastases than controls. Further, exogenous 
IGF-I administration in both controls and LID mice increased the rate of tumour progression and 
metastases compared to mice treated with saline [47].  
 
Findings from human in vivo research examining IGF and CRC staging have produced varying 
results [23,25,26,48,49]. Prospective samples from men and women undergoing a colonoscopy 
identified high-risk adenomas were positively associated with serum IGF-I and inversely associated 
with IGFBP-3 [26]. Supporting this, in a cohort of 125 CRC patients, higher serum concentrations 
of IGF-I were found in those with metastases compared to those with localised CRC [25]. Similar 
findings for IGF-I and adenoma severity were reported by Jacobs et al. [49]. IGF-II has also been 
linked to CRC severity with higher serum levels found in concurrence with secondary cancers [23]. 
In contrast to these results, no significant differences in serum IGF-I were reported with patients 
who had moderate (adenoma) and more advanced (carcinoma) colon cancers [48]. Nonetheless, the 
weight of the limited available evidence tends to support a positive relationship between IGF-I/IGF-
II and CRC specific mortality and an inverse relationship between IGFBP-3 and CRC specific 
mortality.  
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Given the pathways by which IGF-I and IGF-II stimulate cellular proliferation, the expression of 
IGF-IR and IGF-IIR in colonic carcinomas is likely to influence tumour progression. A high 
presence of these receptors in tissues would allow for enhanced activation of intracellular growth 
processes via IGF signalling. Positive tissue staining for IGF-IR has been more frequently identified 
in primary and high risk CRCs in comparison to non-cancerous adenomas and normal tissue 
[50,51]. Further research has identified IGF-IR and IGF-IIR gene expression to be 2.5 and 5 times 
higher, respectively, in malignant tissue compared to adjacent non-cancerous tissue [52]. Despite 
this finding, the IGF-IIR is not thought to influence tumorigenic potential as it lacks the capacity to 
initiate mitogenic behaviours [36]. 
 
In vitro research has examined markers of the IGF axis after CRC diagnosis to determine their 
relationship with disease-specific mortality. Wolpin et al. [53] addressed this among 373 
participants over 13 years, and found no associations between pre-diagnosis IGF-I and IGFBP-3, 
and mortality in those who developed CRC. Given that lifestyle factors such as diet, obesity and PA 
are known to influence IGFs [28,38], failure to include these confounders into the analysis may 
have contributed to the lack of significant findings with regard to IGF-I and IGFBP-3. Following 
CRC diagnosis, higher circulating IGFBP-3 has been correlated with a greater response to 
chemotherapy, arrested rate of tumour progression, and an increase in overall survival [54].  
 
The varied physiological findings reviewed above highlight the need for robust interventional 
designs to clarify the relationships between IGF-I, IGFBP-3 and CRC mortality. Larger sample 
sizes coupled with improved assays that more precisely measure how IGF-I, IGF-II and IGFBP-3 
influence cellular growth will advance understanding of these relationships.  In addition, 
confounding factors such as energy intake and PA following CRC diagnosis need to be either 
controlled for or accurately monitored. Notwithstanding these limitations, there is strong evidence 
to support a mechanistic link between IGFs and heightened CRC mortality following diagnosis, 
whereby increased levels of IGFBP-3 and decreased circulating levels of IGF-I and IGF-II are 
associated with reduced disease-specific mortality.  
 
3.0 Physical Activity and the Insulin-like Growth Factor Axis  
The physiological response of IGFs to PA is inconsistent; increases, decreases and no change in the 
IGF axis have been reported in cancer and non-cancer populations [55-61]. While the reason for 
this inconsistency is not clear, some researchers believe that negative energy balance may underlie 
the mechanism/s [57], while others purport that it may be more closely related to energy flux [55] 
and physical conditioning [56]. Although limited, there is evidence from trials involving CRC 
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populations to indicate that changes in these biomarkers driven by PA can have favourable 
outcomes for disease-specific mortality [14].  
 
Only one intervention study has investigated the influence of PA on the IGF axis in a CRC 
population. Following 12 weeks of unsupervised PA of 18 to 27 MET-hours per week, significant 
increases in IGF-I and IGFBP-3 were found [62]. Given that the intervention was unsupervised and 
adherence was measured via a self-reported questionnaire, the precise quantity and intensity of PA 
completed is unknown. Furthermore, prospective evidence demonstrated a one standard deviation 
increase in IGFBP-3 was associated with a 51% reduction in cancer-specific death for those who 
were physically active [63]. The same association was not seen for inactive individuals or for IGF-1 
[63]. This indicates that PA is capable of eliciting a beneficial shift in disease-specific mortality that 
is manifested by a measureable biochemical change. Whilst it cannot be concluded without further 
research why the IGF-I response does not reflect that of IGFBP-3, there likely exists a delicate 
interplay between the IGF axis and other exercise-induced biochemical responses.     
 
Although not within the subset of CRC, research in other cancer pathologies has examined the 
relationship between the IGF axis and PA. In a cohort of 26 males diagnosed with prostate cancer 
and currently receiving androgen deprivation therapy, it was found that IGFBP-3 significantly 
increased and IGF-I significantly decreased in men undertaking a six month resistance training 
program [58]. No significant changes in these biomarkers were reported for men in the aerobic 
training arm. Although no analysis of this dissonance was mentioned in the paper, it is interesting to 
note the discrepancy with regard to the exercise prescription in both treatment arms. Those in the 
resistance training group were given a set of exercises to complete in the program whereas those in 
aerobic group were encouraged to exercise at 60-80% of their age-predicted maximum heart rate 
via feedback from a wristwatch monitor. No baseline test was completed to confirm this heart rate 
range, therefore the intensity range completed by participants in the aerobic group may have been 
inadequate to elicit changes in the IGF axis that those in the resistance training group experienced.  
 
Several studies have measured the response of IGFs to a PA intervention in breast cancer survivors. 
Fairey et al. [61] tracked the changes in IGF-I, IGF-2 and IGFBP-3 following 15 weeks of moderate 
intensity aerobic exercise; significant increases in IGFBP-3 and decreases in IGF-I were found, 
including decreases in their molar ratio, which is thought to reflect bioactive IGF-I.  More recent 
research by Irwin et al. [59] tracked breast cancer survivors over a 6 month randomised controlled 
trial, and found similar results for IGF-I but significant decreases in IGFBP-3 compared to pre-
intervention levels.  
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Schmitz et al. [64] investigated the role of resistance training on the IGF axis in breast cancer 
survivors. Six months of resistance training resulted in significant reductions in IGF-II however no 
significant changes in IGF-I were reported. Compared to Fairey et al. [61], a higher percentage of 
participants in this study were undergoing chemotherapy, which is known to alter IGF-I levels 
(Bonani, 2001) and therefore may have muted the biochemical response to PA. 
 
In addition to PA, negative energy balance through dietary restriction may lead to a reduction in 
IGF-I [31]. Several studies involving healthy populations have attempted to address this by 
employing dietary controls in addition to a PA intervention. Nemet and colleagues [57] found IGF-I 
to only decrease following seven days of aerobic exercise when participants were in a negative 
energy balance (assisted via dietary restriction).  In agreement, Smith et al. [65] found no 
differences in groups who experienced the same negative energy balance through PA or diet alone. 
The volume and intensity of PA required to lower IGF-I is not known and it may be that without a 
negative energy balance, longer interventions at a higher intensity or volume of PA are required for 
significant IGF-I changes to occur. Rarick et al. [55] addressed this idea of energy flux which 
accounts for the absolute level of energy expenditure and intake under conditions of energy balance. 
They found that energy balance and baseline aerobic fitness had no impact on IGF-I or IGFBP-3 
response. These findings are in contrast to those of Smith et al. [65] and Nemet et al. [57], further 
confounding the relationship between PA and the IGF axis.  
 
Given that dietary intake influences IGF-I levels, controlling for this variable in the days preceding 
blood sampling is crucial to understanding the precise impact of PA on the IGF axis [31]. Many of 
the studies investigating the PA/IGF association have not reported dietary intake control prior to 
testing. Further, assays that only measure total IGF-I in circulation rather than free IGF-I or IGF-IR 
activation have generally been used. This measure does not differentiate between IGF-I that is 
free/bioactive or bound in binary and ternary units (and therefore unable to interact with cell surface 
receptors).  
 
4.0 Conclusions and Future Directions 
While the benefits of PA for the prevention of CRC and reduction in disease-specific mortality 
post-diagnosis are well established, the physiological mechanisms by which PA can mediate these 
outcomes remains to be determined. Of the several biological pathways that have been considered, 
the IGF axis is the most plausible mechanism and has subsequently received the most interest. 
Following diagnosis from CRC, there is evidence to suggest that a decrease in IGF-I and an 
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increase in IGFBP-3 can reduce disease-specific mortality. While there is evidence to suggest that 
PA may influence IGF-I and IGFBP-3, intervention studies involving a structured PA regime for 
CRC populations examining changes in the IGF axis are required. Understanding the frequency, 
intensity, duration and mode of exercise that each will potentially influence the IGF axis, reduce the 
incidence of CRC and improve survival is needed to inform the development of specific PA 
guidelines for CRC survivors - guidelines that currently do not exist.  
 
  
 
72 
References 
1. J F, HR S, F B, D F, C M, DM P. GLOBOCAN 2008 v2.0, Cancer Incidence and 
Mortality Worldwide: IARC CancerBase No. 10 [Internet]. [Internet]. International 
Agency for Research on Cancer. Lyon, France; 2010 [cited 2013 May 2]. Available 
from: http://globocan.iarc.fr 
2. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the 
world: comparative risk assessment of nine behavioural and environmental risk factors. 
The Lancet. Elsevier; 2005;366(9499):1784–93.  
3. Ballard-Barbash RR, Friedenreich CMC, Courneya KSK, Siddiqi SMS, McTiernan 
AA, Alfano CMC. Physical activity, biomarkers, and disease outcomes in cancer 
survivors: a systematic review. J Natl Cancer Inst. 2012 Jun 5;104(11):815–40.  
4. Denlinger CS, Engstrom PF. Colorectal Cancer Survivorship: Movement Matters. 
Cancer Prevention Research. 2011 Apr 3;4(4):502–11.  
5. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, et al. A 
prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk 
of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000 
Apr;9(4):345–9.  
6. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the 
evidence. J Nutr. 2001 Nov;131(11 Suppl):3109S–20S.  
7. Chi F, Wu R, Zeng Y-C, Xing R, Liu Y. Circulation insulin-like growth factor peptides 
and colorectal cancer risk: an updated systematic review and meta-analysis. Mol Biol 
Rep. Springer Netherlands; 2012 Dec 27;:1–8.  
8. Samad AKA, Taylor RS, Marshall T, Chapman MAS. A meta-analysis of the 
association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 
2005 May;7(3):204–13.  
9. Wolin KY, Yan Y, Colditz GA, Lee I-M. Physical activity and colon cancer 
prevention: a meta-analysis. Br J Cancer. 2009 Feb 24;100(4):611–6.  
10. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of 
proximal and distal colon cancers: a systematic review and meta-analysis. JNCI Journal 
of the National Cancer Institute. 2012 Oct 17;104(20):1548–61.  
11. Meyerhardt JAJ, Giovannucci ELE, Ogino SS, Kirkner GJG, Chan ATA, Willett WW, 
et al. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009 Dec 
13;169(22):2102–8.  
12. Meyerhardt JA. Physical Activity and Survival After Colorectal Cancer Diagnosis. 
Journal of Clinical Oncology. 2006 May 25;24(22):3527–34.  
 
73 
13. Meyerhardt JA. Impact of Physical Activity on Cancer Recurrence and Survival in 
Patients With Stage III Colon Cancer: Findings From CALGB 89803. Journal of 
Clinical Oncology. 2006 May 25;24(22):3535–41.  
14. Haydon AMM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and 
body size on survival after diagnosis with colorectal cancer. Gut. 2006 Jan;55(1):62–7.  
15. Boyle T. Physical Activity and Colon Cancer: Timing, Intensity, and Sedentary 
Behavior. 2012 May 1;6(3):204–15.  
16. Garber CE, Blissmer B, Deschenes MR, Franklin BA, LaMonte MJ, Lee I-M, et al. 
Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, 
Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults. Medicine & 
Science in Sports & Exercise. 2011 Jul;43(7):1334–59.  
17. Lissner L. Recall of Physical Activity in the Distant Past: The 32-Year Follow-up of 
the Prospective Population Study of Women in Goteborg, Sweden. American Journal 
of Epidemiology. 2004 Feb 1;159(3):304–7.  
18. K S Courneya CMBSGPOJVCMFHJAMDBDTHDRMM. The Colon Health and Life-
Long Exercise Change trial: a randomized trial of the National Cancer Institute of 
Canada Clinical Trials Group. Science. Multimed Inc; 2008 Dec 1;15(6):271.  
19. Wolin KY, Lee I-M, Colditz GA, Glynn RJ, Fuchs C, Giovannucci E. Leisure-time 
physical activity patterns and risk of colon cancer in women. Science. 
2007;121(12):2776–81.  
20. Harriss DJ, Cable NT, George K, Reilly T, Renehan AG, Haboubi N. Physical Activity 
Before and After Diagnosis of Colorectal Cancer. Science. 2007;37(11):947–60.  
21. Takahashi HH, Kuriyama SS, Tsubono YY, Nakaya NN, Fujita KK, Nishino YY, et al. 
Time spent walking and risk of colorectal cancer in Japan: the Miyagi Cohort study. 
Eur J Cancer Prev. 2007 Sep 30;16(5):403–8.  
22. JONES JI, CLEMMONS DR. Insulin-like growth factors and their binding proteins: 
biological actions. Endocr Rev [Internet]. 1995 Feb;16(1):3–34. Available from: 
http://ezproxy.library.uq.edu.au/login?url=http://www.ncbi.nlm.nih.gov/pubmed?otool
=iauqulib 
23. Barozzi CC, Ravaioli MM, D'Errico AA, Grazi GLG, Poggioli GG, Cavrini GG, et al. 
Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad 
panel. Cancer. 2002 Jan 31;94(3):647–57.  
24. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like 
growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and 
meta-regression analysis. Lancet. 2004 Apr 24;363(9418):1346–53.  
 
74 
25. Kukliński A, Kamocki Z, Cepowicz D, Gryko M, Czyżewska J, Pawlak K, et al. 
Relationships between insulin-like growth factor i and selected clinico-morphological 
parameters in colorectal cancer patients. Pol Przegl Chir. 2011 May;83(5):250–7.  
26. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'dwyer ST. High-risk 
colorectal adenomas and serum insulin-like growth factors. Science. 2001 
Jan;88(1):107–13.  
27. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and 
neoplasia. Nat Rev Cancer. 2004 Jul;4(7):505–18.  
28. Gapstur SM, Kopp P, Chiu BC-H, Gann PH, Colangelo LA, Liu K. Longitudinal 
associations of age, anthropometric and lifestyle factors with serum total insulin-like 
growth factor-I and IGF binding protein-3 levels in Black and White men: the 
CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prev. 2004 
Dec;13(12):2208–16.  
29. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. 
Genetic and environmental components of interindividual variation in circulating levels 
of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. Science. American Society for Clinical 
Investigation; 1996 Dec 1;98(11):2612–5.  
30. Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J, et al. Insulin-like 
growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding 
proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab 
Anal. 1999;13(4):166–72.  
31. Clemmons DR, Underwood LE. Nutritional Regulation of IGF-I and IGF Binding 
Proteins. Annu Rev Nutr.  Annual Reviews  4139 El Camino Way, P.O. Box 10139, 
Palo Alto, CA 94303-0139, USA; 1991 Jul;11(1):393–412.  
32. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development 
and progression. J Natl Cancer Inst. 2000 Sep 20;92(18):1472–89.  
33. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological 
functions for insulin-like growth factors. Physiol Rev. 1996 Oct;76(4):1005–26.  
34. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, et 
al. The Insulin-like Growth Factor I Receptor Protects Tumor Cells from Apoptosis in 
Vivo. Cancer Res. 1995 Jun 1;55(11):2463–9.  
35. Frattali AL, Pessin JE. Relationship between alpha subunit ligand occupancy and beta 
subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J 
Biol Chem. ASBMB; 1993;268(10):7393–400.  
36. O'Dell SD, Day INM. Molecules in focus Insulin-like growth factor II (IGF-II). The 
 
75 
International Journal of Biochemistry & Cell Biology. 1998 Jul;30(7):767–71.  
37. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy 
man. Estimations of half-lives and production rates. Acta Endocrinol. 1989 
Dec;121(6):753–8.  
38. Gatti RR, De Palo EFE, Antonelli GG, Spinella PP. IGF-I/IGFBP system: metabolism 
outline and physical exercise. J Endocrinol Invest. 2012 Jun 30;35(7):699–707.  
39. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF 
actions. Mol Cell Endocrinol. 1998 May 25;140(1-2):19–24.  
40. Kelley KMK, Oh YY, Gargosky SES, Gucev ZZ, Matsumoto TT, Hwa VV, et al. 
Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. 
The International Journal of Biochemistry & Cell Biology. 1996 May 31;28(6):619–37.  
41. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding 
proteins. Endocr Rev. 2002 Dec;23(6):824–54.  
42. Giovannucci E, Pollak M, Platz EA, Willett WC, Stampfer MJ, Majeed N, et al. 
Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal 
adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res. 2000 Apr;10 
Suppl A:S30–1.  
43. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective 
study of colorectal cancer risk in men and plasma levels of insulin-like growth factor 
(IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999 Apr 7;91(7):620–5.  
44. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, et al. 
Serum C-Peptide, Insulin-Like Growth Factor (IGF)-I, IGF-Binding Proteins, and 
Colorectal Cancer Risk in Women. J Natl Cancer Inst. 2000;92(19):1592–600.  
 
45. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 
and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of 
Chinese men in Shanghai. Br J Cancer. Nature Publishing Group; 2001;85(11):1695.  
46. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. 
SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) [Internet]. 
National Cancer Institute. Bethesda, MD; 2012 [cited 2013 Mar 26]. Available from: 
http://seer.cancer.gov/statfacts/html/colorect.html#survival 
47. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth 
factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002 Feb 
15;62(4):1030–5.  
48. Glass AR, Kikendall JW, Sobin LH, Bowen PE. Serum concentrations of insulin-like 
 
76 
growth factor 1 in colonic neoplasia. Acta Oncol. 1994;33(1):70–1.  
49. Jacobs ET, Martinez ME, Alberts DS, Ashbeck EL, Gapstur SM, Lance P, et al. Plasma 
Insulin-Like Growth Factor I Is Inversely Associated with Colorectal Adenoma 
Recurrence: A Novel Hypothesis. Cancer Epidemiology Biomarkers & Prevention. 
2008 Feb 4;17(2):300–5.  
50. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, et al. Expression of 
insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999 
Oct;30(10):1128–33.  
51. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI, et al. Enhanced 
levels of insulin-like growth factor messenger RNA in human colon carcinomas and 
liposarcomas. Cancer Res. 1986 Dec;46(12 Pt 1):6169–73.  
52. S Freier OWMEAFRDINTSESIR. Expression of the insulin-like growth factors and 
their receptors in adenocarcinoma of the colon. Science. BMJ Group; 1999 May 
1;44(5):704.  
53. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the 
Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic 
Colorectal Cancer. Journal of Clinical Oncology. 2009 Jan 8;27(2):176–85.  
54. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, et al. 
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in 
Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. Clinical Cancer 
Research. 2008 Dec 15;14(24):8263–9.  
55. Rarick KR, Pikosky MA, Grediagin A, Smith TJ, Glickman EL, Alemany JA, et al. 
Energy flux, more so than energy balance, protein intake, or fitness level, influences 
insulin-like growth factor-I system responses during 7 days of increased physical 
activity. Journal of Applied Physiology. 2007 Oct 31;103(5):1613–21.  
56. Rosendal L, Langberg H, Flyvbjerg A, Frystyk J, Ørskov H, Kjær M. Physical capacity 
influences the response of insulin-like growth factor and its binding proteins to 
training. Journal of Applied Physiology. 2002 Nov;93(5):1669–75.  
57. Nemet D, Connolly PH, Pontello-Pescatello AM, Rose-Gottron C, Larson JK, Pietro 
Galassetti, et al. Negative energy balance plays a major role in the IGF-I response to 
exercise training. Journal of Applied Physiology. 2003 Dec 31;96(1):276–82.  
58. Daniel Santa Mina MKCSMHAPTCGAGMJTPR. Exercise effects on adipokines and 
the IGF axis in men with prostate cancer treated with androgen deprivation: A 
randomized study. Canadian Urological Association Journal. Canadian Medical 
Association; 7(11-12):E692.  
 
77 
59. Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, et al. 
Randomized controlled trial of aerobic exercise on insulin and insulin-like growth 
factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer 
Epidemiol Biomarkers Prev. 2009 Jan;18(1):306–13.  
60. Schmitz KH. Safety and Efficacy of Weight Training in Recent Breast Cancer 
Survivors to Alter Body Composition, Insulin, and Insulin-Like Growth Factor Axis 
Proteins. Cancer Epidemiology Biomarkers & Prevention. 2005 Jul 1;14(7):1672–80.  
61. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Effects of exercise 
training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-
like growth factor binding proteins in postmenopausal breast cancer survivors: a 
randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):721–
7.  
62. Lee DH, Kim JY, Lee MK, Lee C, Min J-H, Jeong DH, et al. Effects of a 12-week 
home-based exercise program on the level of physical activity, insulin, and cytokines in 
colorectal cancer survivors: a pilot study. Support Care Cancer. 2013 May 2.  
63. Haydon AMM. Physical activity, insulin-like growth factor 1, insulin-like growth 
factor binding protein 3, and survival from colorectal cancer. Gut. 2006 May 
1;55(5):689–94.  
64. Schmitz KH, Ahmed RL, Yee D. Effects of a 9-month strength training intervention on 
insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and 
IGFBP-3 in 30-50-year-old women. Cancer Epidemiol Biomarkers Prev. 2002 
Dec;11(12):1597–604.  
65. Smith AT, Clemmons DR, Underwood LE, Ben-Ezra V, McMurray R. The effect of 
exercise on plasma somatomedin-C/insulinlike growth factor I concentrations. Metab 
Clin Exp. 1987 Jun;36(6):533–7.  
 
  
 
78 
5.2 The influence of high-intensity compared with moderate-intensity exercise training on 
cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised 
controlled trial 
 
Abstract 
Purpose: Following colorectal cancer diagnosis and anti-cancer therapy, declines in 
cardiorespiratory fitness and body composition lead to significant increases in morbidity and 
mortality. There is increasing interest within the field of exercise oncology surrounding potential 
strategies to remediate these adverse outcomes. This study compared four weeks of moderate (MIE) 
and high intensity exercise (HIE) training on peak oxygen consumption (V̇O2peak) and body 
composition in colorectal cancer survivors. Methods: Forty-seven post-treatment colorectal cancer 
survivors (HIE=27 months post-treatment; MIE=38 months post-treatment) were randomised to 
either HIE [85-95% peak heart rate (HRpeak)] or MIE (70% HRpeak) in equivalence with current 
physical activity guidelines and completed 12 training sessions over four weeks. Results: HIE was 
superior to MIE in improving absolute (p=0.016) and relative (p=0.021) V̇O2peak. Absolute (+0.28 
L.min-1, p<0.001) and relative (+3.5 ml.kg-1.min-1, p<0.001) V̇O2peak were increased in the HIE 
group but not the MIE group following training. HIE led to significant increases in lean mass 
(+0.72 kg, p=0.002) and decreases in fat mass (-0.74 kg, p<0.001) and fat percentage (-1.0%, 
p<0.001) whereas no changes were observed for the MIE group. There were no severe adverse 
events. Conclusions: In response to short-term training, HIE is a safe, feasible and efficacious 
intervention that offers clinically meaningful improvements in cardiorespiratory fitness and body 
composition for colorectal cancer survivors. Implications for Cancer Survivors: HIE appears to 
offer superior improvements in cardiorespiratory fitness and body composition in comparison to 
current physical activity recommendations for colorectal cancer survivors and therefore may be an 
effective clinical utility following treatment. 
 
Introduction 
Colorectal cancer is one of the most prevalent cancers worldwide; with the second and third highest 
mortality rates for men and women, respectively, it represents a significant proportion of the health 
burden attributable to cancer [161]. Following diagnosis and anti-cancer therapy (locoregional and 
systemic), many cancer survivors experience acute and chronic toxicities that increase morbidity 
and mortality [162, 163]. There is increasing interest in the clinical utility of exercise-oncology as 
an adjunctive therapy for improving prognosis following colorectal cancer diagnosis via 
remediation of adverse clinical outcomes [163].  
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Cardiorespiratory fitness appears to be a critical prognostic factor across the oncology continuum 
[164]. Compared with low cardiorespiratory fitness (measured by peak oxygen consumption 
[V̇O2peak]), moderate and high cardiorespiratory fitness has been associated with a 33% and 44% 
reduction in colorectal cancer incidence, respectively [164]. Following a cancer diagnosis, 
cardiorespiratory fitness has been shown to predict cancer mortality in men [139] and women [165]. 
Indeed meta-analytical conclusions indicate that compared with lower cardiorespiratory fitness 
levels, higher cardiorespiratory fitness is associated with a 45% reduction in cancer-specific 
mortality [166]. In addition to the strong relationship between cardiorespiratory fitness and 
mortality, cardiorespiratory fitness has also been shown to be an important predictor of morbidity 
following major colonic [43] and rectal [44] cancer surgery. Recent data have shown that in pre-
operative rectal cancer patients, neoadjuvant chemotherapy leads to a decrease in V̇O2peak of 
between 1.4 and 4.0 ml.kg-1.min-1 [41, 42]. These decrements following anti-cancer therapy in 
conjunction with the poor prognostic relationship between low cardiorespiratory fitness and cancer 
morbidity and mortality demonstrate the clinical importance of improving cardiorespiratory fitness 
within the oncology setting.  
 
Mechanistic underpinnings of the reduction in cardiorespiratory fitness following anti-cancer 
therapy appear to be determined by a multitude of central factors such as cardiac and pulmonary 
function, as well as peripheral factors including haematological, vascular and skeletal muscle 
function [163]. Recent pilot data strengthens the mechanistic relationship between reductions in 
cardiorespiratory fitness and skeletal muscle function, with significant reductions in mitochondrial 
function following neoadjuvant chemotherapy observed in rectal cancer patients [42]. This 
reduction in mitochondrial function and subsequent impairment of oxidative phosphorylative 
capacity may be further compounded by a reduction in skeletal muscle mass. Skeletal muscle 
atrophy or cachexia is a common comorbidity following diagnosis and anti-cancer treatment 
characterised by ongoing loss of muscle mass, with or without loss of fat mass, leading to 
progressive impairment in function [167-169]. The presence of cachexia has been shown to increase 
premature mortality rates in patients with advanced colorectal carcinoma [170]. Whilst the clinical 
presentation of advanced cancer cachexia is physically distinguishable, less obvious or ‘hidden’ 
conditions such as pre-cachexia or sarcopenic obesity (muscle mass loss masked by adipose tissue 
hypertrophy) are of perhaps greater clinical importance as these stages may be more responsive and 
amenable to therapeutic interventions as compared with advanced states of cachexia [167, 169]. 
Alluding to the clinical importance of body composition following cancer diagnosis, the presence of 
sarcopenic obesity in colorectal cancer survivors is associated with impaired physical function as 
well as an increase in premature mortality [49].  
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Collectively, reductions in cardiorespiratory fitness, skeletal muscle mass and an increase in 
adipose tissue present a series of adverse comorbidities for colorectal cancer survivors that can 
severely impair prognosis following treatment. Aerobic exercise training has been suggested to be 
one of the most effective therapeutic strategies to combat cancer cachexia through remediation of 
mitochondrial and oxidative phosphorylation dysfunction [171]. Additionally, aerobic exercise 
training is arguably the most effective method of facilitating improvements in cardiorespiratory 
fitness and thereby presents itself as a potentially effective therapy to combat the aforementioned 
adverse clinical outcomes associated with colorectal cancer survivorship. Within the scope of 
aerobic exercise, a recent meta analysis demonstrated high intensity exercise (HIE) to be more 
efficacious in improving cardiorespiratory fitness compared with moderate intensity exercise (MIE) 
in patients with cardio-metabolic disease [172]. Whilst one previous trial has utilised an 
intervention that included HIE in colorectal cancer survivors [173], no study to-date has 
investigated the comparative effectiveness of HIE and MIE to determine the most effective aerobic 
intensity prescription for improvements in cardiorespiratory fitness and body composition. The aim 
of this randomised controlled trial was to compare the effect of a short-term HIE or MIE aerobic 
exercise intervention as a potential clinical utility to promote improvements in cardiorespiratory 
fitness and body composition in colorectal cancer survivors. It was hypothesised that HIE would 
result in greater improvements in cardiorespiratory fitness and body composition compared to MIE.  
 
Methods 
Participants 
Men and women previously diagnosed with histologically-confirmed colorectal cancer were 
recruited from Brisbane (Queensland, Australia) for this randomised controlled trial. Participants 
recruited for this intervention are included as part of the first phase of a larger ongoing trial. 
Inclusion criteria were as follows: (i) aged ≥ 18 years old; (ii) ≥ one-month post-treatment for 
colorectal cancer and not anticipating undergoing treatment during the study period; and (iii) free of 
any musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may 
have prevented safe completion of the exercise demands of the study. Potential participants were 
contacted either through access to the population based Queensland Cancer Registry according to 
previously described procedures [174] or from an existing cohort of colorectal cancer survivors 
[175]. Participants were required to obtain physician consent for participation in the program, and 
were individually screened via a medical history form and interview with the investigators to 
determine eligibility.  
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Study Protocol 
This study was granted ethical approval by the Human Ethics Committee of The University of 
Queensland and written informed consent was obtained from all subjects prior to commencing the 
study. Date of diagnosis and cancer stage information was extracted from pathology reports. 
Following recruitment, participants completed a familiarisation session consisting of a test of peak 
oxygen consumption (V̇O2peak) to assess cardiorespiratory fitness (detailed below). Following 
familiarisation (≥ seven days), participants completed a baseline testing session consisting of an 
assessment of body composition (detailed below) and a V̇O2peak test. Following baseline testing, a 
researcher independent to the study stratified the participants according to age (< 55 or ≥ 55 years) 
and sex and then randomised them via a random number generating process to either HIE or MIE 
(detailed below) at a ratio of 2:1, respectively. This randomisation ratio was implemented for two 
reasons: firstly to account for a potentially inflated dropout rate as the feasibility of a HIE 
intervention in this population has not been reported; and secondly to allow for appropriate sample 
sizes for future phases of this ongoing trial. Both HIE and MIE groups trained three times per week 
for four weeks. Between three and seven days following the final exercise session, participants 
completed endpoint testing involving identical procedures to those used at baseline testing.  
 
Physiological Performance  
V̇O2peak testing was completed using a cycle ergometer (Lode Excalibur Sport, Lode B.V., 
Groningen, Netherlands) and a portable metabolic cart system (ParvoMedics TrueOne 2400, Sandy, 
USA). Expired air was analysed for oxygen consumption (V̇O2), carbon dioxide production 
(V̇CO2); the fraction of oxygen and carbon dioxide in expired air (FEO2 and FECO2) were sampled 
every 15 seconds during exercise from a mixing chamber, while total ventilation (V̇E) was recorded 
every 15 seconds using a turbine ventilometer (Morgan, Model 096, Kent, England). The gas 
analysers were calibrated immediately prior to testing and validated after each test using a certified 
beta gas mixture (BOC, Brisbane, Australia). The ventilometer was calibrated before each test using 
a 3 L syringe (Hans Rudolph Inc., Shawnee, USA) in accordance with the manufacturer’s 
instructions. Blood pressure was measured against contraindications to exercise testing [176]. The 
V̇O2peak testing protocol, modified from Wasserman et al. [177], began with three minutes of rest 
for respiratory normalisation, followed by four minutes of warm up at a resistance of 50 W.  
Thereafter, the electronic resistance provided by the cycle ergometer increased incrementally by 20-
30 W.minute-1.  Participants cycled at a cadence between 60 and 70 revolutions per minute 
throughout the test. Heart rate was continuously recorded throughout exercise using a heart rate 
monitor (Polar FT1, Polar, Kempele, Finland) and blood pressure (DuraShock Sphygmomanometer, 
Welch Allyn, New York, USA) was recorded every two minutes throughout the test.  At the 
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conclusion of each minute, participants indicated their rating of perceived exertion (RPE) on the 
Borg 6-20 scale [178]. The test was terminated when participants reached volitional fatigue or at the 
discretion of the researcher in accordance with the indications for exercise test termination as 
outlined by the American College of Sports Medicine [176]. V̇O2peak was recorded as the mean of 
the two highest 15-second V̇O2 epochs. Peak power output (PPO) was determined by the addition 
of the highest completed power level and the fraction of time spent in the incomplete stage 
multiplied by the stage wattage increments: 
Equation 1: 
PPO! = !final!completed!workload + (workload!increment!x!seconds!in!final!stage!×!60!!)!   
Body Composition  
Fat mass, percentage body fat and lean mass were derived by dual energy x-ray absorptiometry 
(DEXA; Hologic Discovery A, Waltham, MA). The coefficients of variation values in our 
laboratory for whole body fat and lean masses are <1.1%. All scans were conducted and analysed 
by two accredited DEXA technicians. All fat and lean mass results are subtotal values (whole body 
minus the head) rather than whole body totals. Height and body mass were measured using a 
stadiometer (Seca, Birmingham, United Kingdom) and electronic scales (A & D Mercury, Pty Ltd, 
Thebarton, Australia), respectively.   
Control Measures 
For each testing session participants were asked to: (i) maintain a hydrated state in the 24 hours 
prior to testing; (ii) abstain from caffeine and alcohol intake for 12 hours prior to testing; and (iii) 
avoid any vigorous, high or unaccustomed moderate intensity exercise or physical activity for the 
48 hours prior to testing which were confirmed via checklist prior to commencing the session. All 
participants were asked to maintain their current diet and level of physical activity outside of the 
training sessions for the duration of the study (i.e. not commencing any unaccustomed dietary or 
physical activity behaviours throughout the duration of the intervention). To quantify and track the 
weekly physical activity behaviours of participants the Godin leisure-time exercise questionnaire 
[125], was completed at both testing time points. The Godin questionnaire has been shown to have 
a modest correlation compared with accelerometry derived measures of physical activity (r = 0.45) 
[179] but demonstrates high test-retest reliability (r = 0.75) [180].  
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Exercise Intervention 
An Accredited Exercise Physiologist (Exercise and Sports Science Australia) supervised all testing 
and exercise training sessions. Both the HIE and MIE sessions were conducted on air- and 
magnetically-braked cycle ergometers (Wattbike Pro, Wattbike Ltd., Nottingham, England) with 
heart rate continuously measured throughout each session (Sunnto Ambit2 S, Suunto Oy, Vantaa, 
Finland). The HIE training sessions commenced with a 10 minute warm up at 50-70% HRpeak 
before commencing 4x4 minute bouts of cycling at 85-95% HRpeak. Each four minute interval was 
interspersed with a three minute period of active recovery at 50-70% HRpeak, totalling 38 minutes for 
the session. The MIE training protocol consisted of 50 minutes of cycling at 50-70% HRpeak. The 
frequency and volume of MIE was established according to current physical activity guidelines 
recommended for cancer survivors [181, 182] and for adults by the American College of Sports 
Medicine for adults (≥ 150 minutes of moderate intensity physical activity per week) [178]. RPE 
was measured at the conclusion of each 4-minute interval in the HIE session and at similarly regular 
intervals during the MIE session (15, 30, 40 and 50 minutes). Power output and cadence were 
continuously measured throughout the sessions and analysed using specialised software (Wattbike 
Expert, Wattbike Ltd., Nottingham, England).  
 
Rates of Completion, Adverse Events, Attendance and Adherence  
Completion rates were calculated as the number of participants that completed baseline testing 
divided by the number that were randomised at the beginning of the intervention. Adverse events 
were defined as ‘any untoward medical occurrence in a participant subject to the intervention’. A 
severe adverse event was defined as any event requiring hospitalisation or causing an inability to 
carry out usual activities. Adverse events were assessed by monitoring and recording during all 
exercise sessions by the supervising Exercise Physiologist.  Attendance to the intervention was 
measured as the number of sessions attended (nattended) divided by the number of sessions prescribed 
(nprescribed):  
 
Equation 2:   attendance! = !!!""#$%#%!×!!!"#$%"&'#(!!!×!100 
 
Adherence to the intervention was assessed within the prescriptive domains of duration and 
intensity. Duration adherence was measured as the duration of the completed session divided by the 
prescribed duration in minutes:  
 
Equation 3:   duration!adherence! = !!!"#$%&'&( !×!!!"#$%"&'#(!!!!×!100 
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Adherence to the prescribed intensity for both the HIE and MIE groups was measured as the mean 
heart rate (HRmean) achieved within the 12 sessions relative to the recorded HRpeak: 
 
Equation 4:   intensity!adherence! = ! !"!"#$!×!12!! !×! "!"#$!!!×!100 
 
The MIE HRmean was calculated as the mean HR recorded at four time points (15, 30, 40 and 50 
minutes) throughout the 50-minute session whereas the HIE HR mean was calculated as the mean 
of the peak HRs recorded during each of the four intervals. Intensity was also concurrently assessed 
as the mean session RPE recorded throughout the intervention, with session RPE calculated as the 
mean of RPE recorded at four time points during both sessions.  
 
Statistical Analysis 
All data were analysed using SPSS (version 22.0; Chicago, IL). Data were assessed for normality of 
distribution using the Shapiro-Wilk test. Analyses included standard descriptive statistics, 
independent t-tests, Mann-Whitney U tests or Chi-squared tests, as appropriate to test for 
differences between the groups at baseline. Non-parametric data were log-transformed and re-
checked for normality prior to univariate within- and between-groups analyses. Differences within 
groups were assessed using paired samples t-tests or the Wilcoxon Signed Rank non-parametric 
test, as appropriate. Differences between groups were assessed using independent t-tests and the 
non-parametric equivalent Mann-Whitney U test where necessary. Statistical significance was 
accepted at an alpha of p < 0.05. Normally distributed data are presented as mean and standard 
deviation (SD) whereas data-requiring log-transformation were re-transformed and are reported as 
the geometric mean and 95% confidence intervals (CI). Data unable to be normally distributed 
using log-transformation were analysed non-parametrically and presented as median, interquartile 
range and 95% CI. .  
 
Results 
 
Participant recruitment and baseline characteristics  
A consort diagram of participant flow throughout the study is detailed in Figure 1. Following 
recruitment and baseline testing, 47 colorectal cancer survivors were randomised. The 
characteristics of participants included within the analyses are shown in Table 1. There were no 
significant differences (p > 0.05) between groups for any of the measured baseline characteristics. 
A previous diagnosis of colon cancer was more prevalent than rectal cancer within both the HIE 
(colon = 70.0%; rectal = 30.0%) and MIE (colon = 82.4%; rectal = 17.6%). Only 30.0% of 
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participants in the HIE and 41.2% of MIE participants underwent surgical treatment without any 
adjunctive therapy whereas the prevalence of treatment with a chemotherapeutic agent was high 
with 66.6% of HIE and 58.6% of MIE participants undergoing adjunctive chemotherapy. 
Participants in the HIE intervention were at a median 27.0 months post-treatment whereas 
participants in the MIE training were 38.0 months post-treatment. Cancer staging was unable to be 
determined for 13 participants, 9 due to insufficient pathology report information and 4 sets of data 
were unable to be accessed due to consent reasons.  
 
Rates of Completion, Adverse Events, Attendance and Adherence  
Study completion rates for the MIE and HIE were 94.1% and 96.7%, respectively, with only one 
participant dropping out in either group (MIE: discontinued the intervention due to personal reasons 
prior to commencing training, HIE: discontinued after six sessions due to ongoing interruptions 
resulting from additional medical diagnostic testing for an unrelated condition). No severe adverse 
events occurred during any exercise testing or training throughout this study. In terms of non-severe 
adverse events during the study, on three occasions for separate participants (two following a HIE 
session and one following exercise testing), participants experienced a symptomatic episode of 
post-exercise hypotension, which was resolved following active recovery, consumption of fluids 
and recovery in the supine position if necessary. On one occasion, a participant experienced an 
aggravation of pre-existing sciatica following a HIE session. Two participants also experienced an 
acute exacerbation of knee pain during a HIE interval related to pre-existing osteoarthritis. In both 
instances the respective sessions were terminated and the issue did not impact subsequent sessions. 
The number of non-severe adverse events between HIE and MIE groups were not statistically 
significantly different (p=0.082). Additionally following the completion of HIE intervals, two 
participants occasionally reported brief feelings of nausea, which were resolved following active 
and passive recovery as well as fluid intake. Attendance rates at sessions across the intervention 
were 100% in both MIE and HIE groups for the 16 and 29 participants that completed the 
intervention in either group (including all participants: MIE = 97.1%; HIE = 97.0%), respectively. 
The mean ± SD duration of the MIE sessions was 50 ± 0 minutes, indicating a 100% adherence rate 
to the prescribed duration. MIE training was completed at a mean ± SD intensity of 73.4% ± 8.4% 
HRpeak (prescribed: 70% HRpeak) and a RPE of 12.0 ± 1.7. The mean ± SD duration of the HIE 
intervals completed during each session was 15.95 ± 0.1 minutes, representing 99.7% of the 
prescribed duration. HIE intervals were completed at an intensity of 91.9% ± 4.2% HRpeak 
(prescribed: 85-95% HRpeak) at a RPE of 14.6 ± 1.2.  
 
Physical activity levels of participants are displayed in Table 2. There were no significant 
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differences between groups at baseline. No significant changes were observed within-groups across 
the intervention, nor between-groups following the intervention (p>0.05). 
 
Physiological Performance 
Changes in cardiorespiratory fitness and power output are shown in Table 2. There were no 
significant differences between the HIE and MIE groups for any variables at baseline. HIE training 
was associated with a mean increase of 0.28 L.min-1 ± 0.28 L.min-1 and 3.5 ml.kg-1.min-1 ± 3.5 
ml.kg-1.min-1 in absolute and relative V̇O2peak, respectively. Improvements in both absolute 
V̇O2peak (p<0.001) and relative V̇O2peak (p<0.001) in the HIE group were significant from 
baseline to endpoint whereas as no significant within-group changes were observed in the MIE 
group. Mean changes in absolute (p=0.016) and relative (p=0.021) V̇O2peak were significantly 
higher in the HIE group than the MIE group. PPO significantly increased following the intervention 
in both the HIE (p<0.001) and MIE (p=0.030) groups. The mean increase of 29.3 W ± 20.7 W in 
response to HIE training was significantly greater than the 11.7 W ± 19.3 W MIE group increase 
(p=0.018). Similar trends in relative PPO were observed with both groups improving from baseline 
to endpoint (p<0.05), with the mean increase in the HIE group being significantly greater than the 
HIE group (p=0.043).  
 
Body composition 
Body composition data are shown in Table 2. A subset of DEXA data from 10 consecutive 
participants (8 HIE and 2 MIE) was unable to be analysed due to equipment malfunction, which 
consequently reduced the sample size for all body composition analyses (excluding body mass) 
within each group. No significant differences were found between HIE and MIE groups at baseline 
for any of the body composition variables. For the HIE group, body mass significantly decreased 
from baseline to endpoint (p=0.005), with mean changes in the HIE group being significantly 
different compared to MIE (p=0.005). Within the HIE group, lean mass significantly increased by a 
mean (SD) change of 0.72 kg ± 0.80 kg from baseline to endpoint (p=0.002). In the HIE group, both 
fat mass (p<0.001) and body fat percentage (<0.001) significantly decreased from baseline to 
endpoint by a mean (SD) change of 0.74 kg ± 0.65 kg and 1.0% ± 1.0%, respectively. No 
significant within-group changes in body composition were observed for the MIE group. No 
significant differences were observed across the intervention between groups for measures of lean 
mass, fat mass or fat percentage, however the whilst the mean decrease in fat mass in the HIE group 
was greater than the MIE group, the difference was not statistically significant (p = 0.060). 
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Discussion 
This study compared the influence of HIE training with MIE training, on cardiorespiratory fitness 
and body composition in colorectal cancer survivors. The findings show that 12 sessions of HIE 
completed over 4 weeks is significantly more effective than MIE in improving absolute and relative 
V̇O2peak and PPO. Furthermore HIE was found to elicit increases in lean mass and decreased body 
mass, fat mass and fat percentage, with no changes associated with MIE in colorectal cancer 
survivors.  
 
To assess the feasibility of the intervention and the subsequent influence on program efficacy we 
assessed the rates of completion, adverse events, adherence and attendance. We found excellent 
completion rates (MIE = 94.1%; HIE = 96.7%) for participants enrolled in this trial, comparable to 
rates reported in other interventions in colorectal cancer survivors [40, 173, 183]. Data regarding 
program safety and adverse events are severely underreported in the current colorectal cancer-
exercise literature [184]. Only one study to date has reported these data in colorectal cancer 
survivors [173], with which our data compares well. Post-exercise hypotension was the most 
common adverse event, and is a well-known post-exercise phenomenon thought to be resultant 
from a peripheral vasodilatory response in the active musculature coupled with a relative decrease 
in sympathetic vasoconstrictive signals to restore homeostasis following exercise cessation [185].  
As compared with moderate intensity, high intensity resistance training has been shown to induce 
greater reductions in post-exercise blood pressure, which may be due to an increased vasodilatory 
response of the working musculature due to the increased muscle volume recruited and metabolic 
demand of higher intensity exercise [186]. To assist in the maintenance of blood pressure, 
activation of a skeletal muscle-pump mechanism, which augments venous return from the periphery 
to central circulation is a critical process to prevent post-exercise hypotension [185]. As such, it is 
strongly recommended that all HIE sessions and V̇O2peak tests are concluded with a period of 
active recovery to promote activation of this muscle-pump mechanism, as abrupt cessation of 
exercise and withdrawal of this muscle-pump can lead to significant decreases in venous return and 
blood pressure [185]. As an additional prospective countermeasure, we recommend that participants 
undertaking HIE maintain adequate fluid intake prior to, during the session and during recovery. 
Water ingestion is known to induce an acute pressor response, leading to increases in sympathetic 
drive and increases in blood pressure [187], a response that has been shown to effectively maintain 
post-exercise blood pressure and prevent hypotension [188]. Exercise-induced gastrointestinal 
discomfort and nausea is also known to occur with greater frequency following high intensity 
exercise when compared with light exercise [189]. The precise causes of this remain to be 
determined however it has been suggested that dehydration, consumption of foods that delay gastric 
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emptying, and as well as splanchnic hypoperfusion resulting from sympathetic splanchnic 
vasoconstriction to shunt blood to the working musculature and organs (inverse of the post-exercise 
hypotension mechanism) may all contribute to symptoms [189]. This further illustrates the 
importance of appropriate nutritional and hydration-monitoring prior to HIE. Given the small 
number and nature of the adverse events from this study and coupled with previous reports [173], 
HIE training appears safe in the clinical setting with appropriate supervision for colorectal cancer 
survivors.  
 
Our attendance rate of 100% for participants in both the HIE and MIE groups who completed the 
intervention (when including all randomised participants: MIE = 97.1%; HIE = 97.0%) was higher 
than previous trials in colorectal cancer survivor populations, which have reported attendance rates 
ranging from 75.8% to 91.0% [40, 173, 190]. Throughout this intervention we also report excellent 
adherence to the duration of both the MIE (100%) and HIE (99.7%) sessions which again is higher 
than previous measures of duration adherence (87.3%) [173]. When considered in conjunction with 
strong rates of adherence to the prescribed exercise intensity, these outcomes suggest that aerobic 
MIE and HIE are highly feasible within a supervised clinical environment for colorectal cancer 
survivors. The median time since treatment for participants undertaking HIE was 27.0 months. 
Whilst HIE was highly feasible at this time point along the post-treatment continuum more research 
is needed to establish the feasibility of HIE at more proximal post-treatment time points. It is the 
view of the authors that establishing the suitability of a patient for HIE at a point along the post-
treatment continuum should not follow a ‘one size fits all’ approach. Rather, decisions regarding a 
patient’s suitability to undertake HIE should be made with consideration of their overall clinical 
presentation and comorbidities, which therefore necessitates consideration on an individual-by-
individual basis with input from the patient’s primary healthcare physician. Given the relatively 
brief duration of our intervention, these feasibility outcomes may be inflated compared to longer 
duration interventions (≥ 12 weeks), however given our results pertaining to the efficacy of the 
intervention on cardiorespiratory fitness and body composition, these data provide novel 
considerations for the design of shorter, highly feasible and efficacious clinical exercise programs 
for colorectal cancer survivors.  
 
The present study demonstrates HIE to be significantly more efficacious than MIE in improving 
absolute (0.28 L.min-1, p=0.016) and relative (3.5 ml.kg-1.min-1, p=0.021) V̇O2peak as well as PPO 
(29.3 W, p=0.018). Only one previous study has measured changes in V̇O2peak in response to 
exercise in colorectal cancer utilising a maximal graded exercise test with direct ventilatory 
measurement similar to the present study. Sellar et al. [173] implemented a longer intervention than 
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the current study (12 weeks) and utilised a combination aerobic and resistance training program 
(aerobic: three sessions/week; interval training; moderate to high intensity progressively increasing 
from 60-75% PPO to 110% PPO; resistance training: two sessions/week; 2-3 sets, 6-15 repetitions 
at 65-85% 1 repetition maximum) and reported significant increases in absolute (0.24 L.min-1; 
p<0.001) and relative (3.0 ml.kg-1.min-1; p<0.001) V̇O2peak as well as PPO (24.0 W), similar to the 
present results. A meta-analysis including three other studies in colorectal cancer survivors 
demonstrated evidence for increases in physical fitness in response to exercise and physical activity 
interventions, however submaximal treadmill tests were used to predict physical fitness, which rely 
on extrapolation of values (e.g. heart rate) to estimate maximal capacity and are therefore less 
accurate than direct measurement at maximal exercise [40, 183, 184, 190]. Meta-analytical data of 
interventions of all cancer patients suggest mean (95% CI) improvements in relative V̇O2peak of 
2.9 ml.kg-1.min-1 (1.16 – 4.64) following supervised exercise training [191]. Whilst our results are 
of a similar magnitude and provide further support for the efficacy of exercise interventions to 
improve cardiorespiratory fitness in oncology populations, previous trials have been of a 
substantially longer duration than the present study, ranging from 8 to 24 weeks of predominantly 
MIE. As no studies have previously used an intervention of such a short duration, it is not possible 
to conclude that similar cardiorespiratory fitness changes similar to the present study were not also 
observed at 4 weeks in other studies. However our data provide evidence that short-term exercise 
training of a higher intensity offers greater physiological adaptations when compared to moderate 
intensity training of the same duration.  This discrepancy between our intervention duration (4 
weeks) and others (≥ 8 weeks) may also explain the lack of V̇O2peak improvement in response to 
MIE in the present study. Cardiorespiratory fitness improvements in response to MIE may require 
longer interventions when compared to HIE, which is largely supported by previous studies in 
cancer survivors of longer durations that are predominantly of a moderate intensity [173, 191]. The 
present data strongly suggest that exercise intensity is a key prescriptive variable in short-term 
exercise interventions, with HIE offering significant increases in cardiorespiratory fitness compared 
with MIE.  
 
In the present study, HIE training led to significant increases in lean mass (0.72 kg ± 0.80kg; 
p=0.005) and reductions in fat mass (-0.74 kg ± 0.65 kg; p<0.001) and body fat percentage (-1.0% ± 
1.0%; p<0.001), whereas no significant changes were observed in response to training for the MIE 
group. Comparably, of the seven exercise-intervention studies conducted exclusively in colorectal 
cancer survivors [40, 75, 173, 183, 190, 192, 193], only two incorporated discrete measurement of 
separate tissues in body composition analysis similar to the present study. Lee et al. [75] used 
bioelectrical impedance analysis in response to a 12 week home-based physical activity program 
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whereas Sellar et al. [173] utilised air displacement plethysmography. No changes in fat percentage, 
lean or fat mass was observed in response to either intervention. Recent meta-analytical data 
demonstrate that in cancer survivors, resistance training interventions conducted over 12 to 52 
weeks are associated with mean (95% CI) increases in lean mass of 1.1 kg (0.8 to 1.4) and 
decreases in body fat percentage of -2.1% (-3.5% to -0.7%) with non-significant changes in fat 
mass [194]. Whilst the magnitude of these changes is greater than in the current study, it is 
promising that improvements in lean mass were seen at all, given that the intervention in the current 
study did not involve resistance training and was shorter in duration than those in the meta-
analyses. These findings however are limited by our reduced sample size due to the unavailability 
of 10 data sets and should be interpreted with caution.  
 
To our knowledge, this is the first trial to demonstrate improvements in both physiological 
performance and body composition following aerobic HIE in cancer survivors. These increases with 
HIE but not MIE provide novel insight into the importance of exercise intensity prescription. The 
HIE prescription within the current study utilised four sets of a four-minute interval duration 
followed by three minutes of active recovery. Within the breadth of high-intensity interval training 
literature, a four-minute interval is considered a ‘long-interval’ (> 60 seconds) and is associated 
with a high physiological demand, incorporating both anaerobic (phosphocreatine system and 
anaerobic glycolysis) and aerobic (oxidative phosphorylation) energetics [195]. The physiological 
demands in terms of energy systems leads to both central and peripheral fatigue in response to long-
interval training [196]. Within this study, the use of an air-braked, high-intensity interval cycle 
ergometer training regime specifically targets the hip and knee extensor musculature, which has 
been previously shown to increase the activity of various oxidative and glycolytic enzymes (citrate 
synthase, succinate dehydrogenase and phosphofructokinase) concurrently with PPO and V̇O2max 
[197-199]. Whilst specific enzymatic measures were not included in the current study, significant 
improvements in PPO in response to HIE (29.3 W; p <0.001) suggest an increase in peripheral 
oxidative and glycolytic capacity to offset peripheral muscular fatigue of the lower limb 
musculature. Increases in mitochondrial biogenesis has been suggested as a primary mechanism 
underlying the HIE-induced peripheral adaptions leading to increases in oxidative capacity [143]. 
Specifically, increases in peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α), 
which is considered the ‘master regulator’ of mitochondrial biogenesis has been shown to increase 
in response to HIE [143, 200-202]. In patients with heart failure, HIE of the same prescription used 
in the present study increased PGC-1α whereas no changes were observed in response to MIE 
[153]. Increases in muscular PGC-1α content have been reported to occur through cellular 
activation of both the 5’-adenosine monophosphate-activated protein kinase and the p38 mitogen-
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activated protein kinase (MAPK) as a result of HIE [143, 201]. The latter is a downstream target of 
the MAPK pathway, which in addition to other key pathways (akt/mammalian target of rapamycin, 
calcium (Ca2+)-dependent pathways), is concurrently an important cellular pathway leading to 
muscular hypertrophy and anabolic development, however this is generally only considered in 
response to resistance training [203, 204]. Evidence to date suggests that HIE is capable of 
promoting MAPK activation and subsequent cellular signalling which can induce both increases in 
mitochondrial content as well as muscular hypertrophy which may explain the increases in lean 
mass observed in HIE but not MIE. Furthermore HIE has been suggested to be more effective than 
MIE in reducing fat mass, hypothesised to occur as a result of exercise-induced increases in fat 
oxidation, catecholamine mediated fat metabolism or appetite suppression [149]. This presents a 
mechanistic hypothesis for the interpretation of the current results that is capable of explaining 
increases in aerobic and anaerobic performance (V̇O2peak and PPO) as well as simultaneous 
increases in lean tissue and decreases in fat mass in response to aerobic HIE but not MIE. Future 
cellular analysis of these pathways is required to provide greater mechanistic scope for the 
interpretation of these findings.  
 
These results have important clinical implications for the therapeutic use of targeted HIE programs 
within the oncology setting. Cardiorespiratory fitness is strongly and inversely associated with both 
mortality following cancer diagnosis [139, 164-166] and morbidity following major colonic and 
rectal surgery [43, 44]. Recent data in male cancer survivors suggest that an increase of 1-metabolic 
equivalent (MET; 3.5 ml.kg-1.min-1) leads to a concurrent 10% decrease in cancer-specific mortality 
risk [164]. The present four-week HIE intervention observed a mean increase in V̇O2peak of 3.5 
ml.kg-1.min-1 (p<0.001), demonstrating the potentially clinically meaningful improvements of HIE 
on cancer prognosis following diagnosis and adjuvant therapy. The prevalence of adjuvant 
chemotherapy was high in the current cohort (HIE = 66.6%; MIE = 58.8%) and given the known 
decrements in V̇O2peak (1.4-4.0 ml.kg-1.min-1) following treatment, the clinical importance of the 
rapid improvements in V̇O2peak observed in the present study are further illustrated [41, 42]. The 
decrease in cardiorespiratory fitness following chemotherapy is thought to be determined primarily 
by a decrease in mitochondrial content and function [42], the amelioration of which is an important 
component of this high intensity prescription as improvements in mitochondrial density and 
function have been reported in response to HIE [205]. Sarcopenic obesity has been associated with 
impaired functional status and increased mortality risk following colorectal cancer diagnosis [49]. 
The present increases in lean mass (0.72 kg; p=0.002) and decreases in fat mass (-0.74 kg; p<0.001) 
in response to HIE but not MIE, may present HIE as an effective intervention to assist in 
remediating reductions in skeletal muscle and increases in adipose tissue following colorectal 
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cancer treatment. With the observed improvements in cardiorespiratory fitness and body 
composition, combined with the short-term accrual of these changes, aerobic HIE appears to offer 
clinically meaningful improvements in colorectal cancer prognosis following diagnosis and 
treatment, superior to that of MIE.   
 
This study has several limitations that are worthy of comment. Firstly we did not implement any 
restrictions on inclusion criteria relating to age, cancer stage, treatment received or time since 
diagnosis or treatment. Given the known effects of adjuvant chemotherapy on cardiorespiratory 
fitness, participants who underwent this treatment may be more receptive to cardiorespiratory 
fitness improvements as a result of lower baseline values when compared to participants who did 
not receive chemotherapy. Furthermore this relationship may extend to differences in time since 
treatment, whereby participants more proximal to final treatment may be more receptive to 
improvements in cardiorespiratory fitness and body composition. Additional sub-analysis according 
to these variables was not possible in the present study due to sample size restrictions, however 
future trials should endeavour to make these considerations wherever possible.  Within this study, 
we used the MIE group as a ‘usual care’ condition as this aligns with current physical activity 
guidelines for cancer survivors and as such there was no true ‘control group’. Following from this, 
our comparison with current physical activity guidelines for cancer survivors meant that controlling 
for total metabolic expenditure in each intervention was not possible. This may limit the 
conclusions that can be drawn regarding the isolated effect of exercise intensity between non-
isoenergetic protocols. Whilst we did not directly compare the exercise volumes of the HIE and 
MIE protocols, a previous study estimated that the same HIE protocol implemented in the present 
study was approximately isoenergetic with 47 minutes of MIE (at 70% HRpeak) in a group of 
patients with the metabolic syndrome [206]. This data provides basic support that the volume of 
exercise completed between the HIE and MIE protocols was somewhat similar, however the non-
isoenergetic nature of these protocols should be acknowledged as a limitation when drawing 
conclusions from these results. In the present study we found no increases in leisure-time exercise 
across either HIE or MIE groups, providing support for the observed changes being resultant from 
the exercise intervention rather than external participation in exercise or physical activity. Whilst 
self-reported levels of physical activity using the Godin questionnaire have been shown to be 
sufficiently reliable [180], recent data has questioned the validity of this method when compared 
with objectively measured levels of physical activity such as tri-axial accelerometry [207]. Whilst 
discrepancies between methods may originate from the focus of self-report data on recreational 
exercise, whereas objective measures capture total physical activity, future research should 
endeavour to use more accurate measures to quantify external exercise and physical activity so as to 
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strengthen conclusions made as being resultant of the intervention rather than external factors. This 
extends to changes in dietary patterns also, in the present study we did not collect dietary records 
expansive enough to validly assess and track changes in dietary habits across the intervention. 
Finally, we only assessed outcomes following four weeks of exercise training and therefore whether 
this intervention resulted in clinically meaningful long-term changes is yet to be determined.  
 
The present study is the first to compare the differential effects of moderate and high intensity 
exercise in any cancer survivorship population. Our results demonstrate HIE to be superior to MIE 
in promoting improvements in V̇O2peak, PPO and in body composition, which were not evident in 
response to MIE. Current guidelines for cancer survivors recommend exercise in accordance with 
general physical activity guidelines (i.e. 150 minutes of moderate intensity or 75 minutes of 
vigorous intensity exercise per week) [182]. Our results indicate that HIE appears to be significantly 
more efficacious than MIE to facilitate improvements in cardiorespiratory fitness and body 
composition for colorectal cancer survivors in the short term.  Given the clinical importance of 
improving cardiorespiratory fitness and body composition in oncology, our results present HIE as a 
time-effective therapeutic utility, which may lead to clinically meaningful improvements in 
colorectal cancer prognosis. 
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5.3 Review of Molecular Mechanisms linking IL-8 to Mitogenesis and Angiogenesis !
Interleukin-8 and Mitogenesis in Colorectal Cancer 
At the cellular level, cancer is characterised by cell proliferation exceeding that of cellular 
apoptosis.  As such, in normal cellular functioning a delicate balance between proliferative and 
apoptotic factors exists and an imbalance towards the former can result in tumorigenesis.  As 
previously described, IL-8 is a cytokine with proliferative qualities whose overexpression has been 
found to correlate with CRC and its progression[3, 64, 66].  Cancer cells, which have both CXCR1 
and CXCR2 receptors, receive IL-8 via autocrine, paracrine, and endocrine avenues; cancer cells 
have been reported to express IL-8 which can then act in a autocrine fashion[3].  It has been 
documented that this transcription of IL-8 within cancer cells is derived from activation of binding 
factors including nuclear factor (NF)-kappa-B, activating protein (AP)-1, and polyomavirus 
enhancer A binding protein (PEA)-3, however the primary source of constitutive IL-8 production is 
via NF-kB and AP-1 binding[208-210]. In a review of the mitogenic effects of IL-8 on cancer cells, 
Zhu and Woll[3] illustrated this pathway in Figure 8.  
 
 
 
This IL-8 can then bind to the CXCR1 and CXCR2 receptors on its parent cell or adjacent CRC 
cells, constituting autocrine or paracrine functioning.  In addition to this source of IL-8, cancer cells 
Sourced(from(Zhu(and(Woll[3].(Fig.(8.(Signal(Pathway(of(IL?8(and(cross?talk(between(IL?8(and(EGFR.((Cancer'
cells' constitutively' transcribe' IL38'mainly' through'NF3kB' and'AP31'binding' in' IL38'promotor.' ' Secreted' IL38'
exerts'its'multiple'functions'on'cells'binding'to'its'receptors'CXCR1'and'2.'IL38'activates'EGFR'via'ADAM'and'
HB3EGF.[3]'
'
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are able to exploit IL-8 in circulation that has been produced in remote cell bodies and deployed to 
the cancer site as a part of the immune response[3].   
 
The binding of this IL-8 to CRC cells triggers a number of intracellular pathways, ultimately 
leading to proliferation[95].  The exact mechanisms underlying this phenomenon are not 
comprehensively understood, however, there has been significant research into the mitogen 
activated protein kinase (MAPK) signalling pathway (flow of this pathway is depicted down the left 
hand-side of Figure 8) [3].  Basis for this claim arises from the fact that within cancer cells 
including those of CRC, it has been found that magnitude of MAPK pathway activation correlates 
well with rates of cell proliferation[1, 67].   
 
Further to this correlation, much research has been conducted into the mechanistic avenues at the 
crux of this observation[1, 3]. Initial CXCR1 and CXCR2 activation, and indeed activation of other 
G protein coupled receptors, is accompanied by transactivation of epidermal growth factor receptors 
(EGFR)[211, 212].  EGFR transactivation is facilitated by a disintegrin and metalloproteinase 
(ADAM)[95].  ADAMs are molecules located on the cell membrane enacting ectodomain shedding 
to prime numerous proteins and receptors by creating bioactive versions[213].  The ectodomain, 
domain portion of a protein that protrudes into the extracellular space allowing for binding to 
receptors on other cell membranes, is cleaved from the molecule leaving a soluble ligand capable of 
receptor activation on the host or adjacent cells[214].  This process of ectodomain shedding is 
required for EGFR activation (reviewed by Blobel[215]).  In CRC cells, IL-8 activation of ADAM 
triggers the release heparin-binding EGF-like growth factor (HB-EGF), capable of causing EGFR 
phosphorylation[95].     
 
Following activation of an EGFR, primes Ras for function by the exchange of its guanosine 
diphosphate for a guanosinetriphosphate molecule[96].  This bioactive Ras molecule can activate a 
kinase cascade that chronologically includes RAF proto-oncogene serine/threonine protein kinase, 
MAPK kinase, MAPK, and extracellular signal-regulated kinases (ERK) 1 and ERK2, triggering a 
variety of transcription factors, including the E2F family and activator protein (AP)-1, with the 
principal task of transcribing cell proliferation genes[1, 3, 96]. 
In the field of CRC, this is by far the most promising pathway with Itoh and colleagues [95] having 
examined the cascade of events in vitro in CRC cell lines with great success, confirming the ability 
for IL-8 to induce cell proliferation via the EGFR-MAPK pathway.  This was done through using 
factors that would inhibitor various parts of this pathway and examining how it effected IL-8-
induced cell proliferation in CRC cell lines[95].  The inhibitors used acted on the ADAM, EGFR, 
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and MAPK portions of the cascade and were all found to significantly inhibit cell proliferation, 
indicating the involvement of these factors in the pathway [95]. It was then the task of this 
experiment to examine certain processes within the postulated pathway.  Confirmation of 
transactivation of EGFR arose as a transient increase of 4.5-fold in EGFR phosphorylation was 
observed in direct response to a treatment of 20ng/ml of IL-8[95].  To determine whether ADAM-
cleavage was involved in this process, an ADAM inhibitor was applied to the experiment, negating 
all EGFR phosphorylation in response to IL-8 treatment[95].  To investigate whether HB-EGF is 
indeed the messenger from ADAM-cleavage to EGFR activation, HB-EGF neutralising antibodies 
were imparted upon the microenvironment and found to significantly hinder IL-8-induce cell 
proliferation[95].  The results of this study provide strong evidence for an important involvement of 
ADAM and EGFR which inturn leads to MAPK signalling in IL-8-induced mitogenesis.  Another 
interesting finding of this study was that in trials without the treatment of an inhibitor there existed 
a dose-response relationship between IL-8 treatment and CRC cell proliferation[95].  Thus, as IL-8 
expression increases there is a concomitant increase in cell proliferation, suggesting that IL-8 is an 
important mediating factor in this process[95].     
 
Another postulated method for IL-8-induced mitogenesis is via nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) pathway[3].  Interestingly, cell proliferation is not a result of 
NF-κB, rather the Rho off-branch of the pathway, as seen in middle portion of Figure 8.  Once IL-8 
binds to either CXCR1 or CXCR2, the Rho-GTPase pathway is activated[81].  The binding of IL-8 
to CXCR1 will cause rapid Rho-GTPase activation whilst CXCR2 binding results in delayed 
activation, either of which affect enzymatic cascades promoting the formation of phospholipase D 
(PLD)[81, 216].  PLD is an enzyme of the phospholipase family with proliferative qualities, thus 
playing a role in cancer[216].  PLD has two isoforms, PLD1 and PLD2, the former of which can be 
activated by the Rho-GTPase pathway[217].  Whilst there is some suggestion that Rho-GTPase 
activation can induce proliferation via this pathway there remains conjecture with no studies being 
conducted in CRC cell lines[216, 218, 219]. Foster and Xu[216] have reviewed this area 
extensively including further discussion of interactions PLD may have with other GTPase families 
and growth factors, other than IL-8, and how that can aid in cell proliferation.    
 
IL-8 appears to be intrinsically linked with mitogenesis in CRC via transactivation of EGFR[1, 3, 
95].  Through ADAM-cleavage, HB-EGF binds to EGFR eliciting a cascade of enzymes 
eventuating with the up regulation of many transcription factors, namely AP-1 and E2F, which 
induce cellular propagation[1, 3].  There also exists some evidence to support the notion that IL-8 
could also induce PLD activation and thus mitogenesis however this is yet to be extensively 
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investigated[3, 216].   
 
Interleukin-8 and Angiogenesis in Colorectal Cancer 
One of the major mechanisms of cellular growth, in normal biological functioning and in cancerous 
tissue, is angiogenesis[97].  With the formation of new blood vessels comes a greater ability for 
delivery of nutrients, oxygen, growth factors, and other blood-borne elements such that supply 
equals demand[97].  Initiated very early in tumour life, angiogenesis is essential to the progression 
and growth of any tumour, including that of CRC[97-99]. CRC-induced angiogenesis is stimulated 
by angiogenic factors, such as IL-8, binding to receptors on endothelial cells in the 
microenvironment [99, 100].  The ability of IL-8 to exert its angiogenic potential on endothelial 
cells has been demonstrated both in vitro and in vivo[89, 101, 102].  Interestingly, the effectiveness 
of IL-8 to induce angiogenesis in endothelial cells is more pronounced in microvasculature than 
macrovasculature[103]. 
 
Endothelial cells have been documented to exhibit both CXCR1 and CXCR2 however there is 
suggestion that only the CXCR2 receptor that possess the ability to initiate angiogenic process[104, 
105]. Any chemokine displaying the ELR motif has the potential to bind to CXCR2 and initiate this 
process, however the abundance of IL-8 produced by the surrounding CRC cells means that it is a 
potent angiogenic factor[104, 105].   
 
The intracellular process driving angiogenesis is the same as that of proliferation previously 
outlined with the additionally property of control and direction[106].  Rather than proliferating in a 
random fashion as is the case in cancer cells, angiogenesis involves the systematic breakdown of 
the extracellular matrix to direct the proliferation of endothelial cells in certain directions and 
structures necessary for neovessel formation[107].  The extracellular matrix is broken down by a 
family of proteinases, matrix metalloproteinase (MMP), with the newly proliferated endothelial 
cells filling the void created[107, 220]. Of important interest is that MMPs, specifically MMP-2 and 
MMP-9, are up regulated in in vitro endothelial cells incubated with IL-8 further implicating IL-8 
as an angiogenic promoter[107].  This phenomenon has been demonstrated in vivo in melanoma, 
prostate cancer, lung cancer, and Kaposi’s sarcoma[108-111].  Whilst no data for CRC exists, it is 
reasonable to assume that CRC-produced IL-8 would up regulate MMPs given that this occurs 
within endothelial cells in the microenvironment which would not differ between cancer types. 
Moreover, Ning et al[112] demonstrated in vivo that CRC cells transfected with IL-8 induced 
angiogenesis in the microenvironment however MMP expression was not measured.  
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In addition to tumour-produced IL-8 acting as a paracrine agent, there is also evidence to suggest 
that endothelial cells can produced IL-8 and work in an autocrine manner[221].  Endothelial cells, 
which exhibit toll-like receptors, have been observed to produce IL-8 thus creating the possibility 
for autocrine activation[222, 223]. Li, et al[221] examined this in vitro and observed that 
endothelial-produced IL-8 could perform in an autocrine manner and inturn mediate cell 
proliferation and angiogenesis.   
 
As such, IL-8 is abundantly expressed in the CRC microenvironment and is a potent angiogenic 
stimulator.  This, in conjunction with its integral role in facilitating proliferation of CRC cells, 
demands the investigation for interventions with the ability to manipulate this variable.  One such 
method previously discussed in this review is exercise and physical activity.  
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5.4 American College of Sports Medicine: Indications for Terminating Exercise Testing  
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5.5 Three Day Food Diary 
 
3 DAY FOOD DIARY 
*Please provide as much detail as possible and include all drinks. 
*Keep in mind you will be required to follow this diet at 3 other time points during the study. 
Day Breakfast Snack Lunch Snack Dinner Snack 
Eg. -Toast with 
honey (2 
slices). 
-Fruit juice 
(1 glass). 
-Chocolate 
biscuit (2 
units). 
-Coffee 
with milk.  
-1 banana. 
-1 Meat pie 
with tomato 
sauce. 
-Can of 
coke 
(350mL).  
N/A -Lasagne 
(medium 
portion). 
-Caesar 
salad (half 
plate). 
 
-Skim milk 
(1 glass). 
-Cadbury 
chocolate 
(10 
squares).  
-1 apple. 
1  
 
 
 
 
 
 
     
2  
 
 
 
 
 
 
     
3  
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5.6 Seven Day Physical Activity Diary  
 
7 DAY ACTIVITY DIARY 
 *Record duration (in mins) that activity was completed for. 
*Add any activity not already listed to ‘other’. 
Activity 1: 2: 3: 4: 5: 6: 7: Eg. 
Gardening        15 
House Work        10 
Walk (leisurely)        - 
Walk (power)        - 
Hiking        - 
Jogging        - 
Cycling        30 
Swim (laps)        - 
Swim (aerobics)        - 
Thai Chi        - 
Aerobics        - 
Dancing        30 
Weights        - 
Tennis        - 
Bowls         - 
Squash        - 
Badminton        - 
Soccer        - 
Cricket        - 
Football        - 
Basketball        - 
Other:        - 
Other:        - 
Other:        - 
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5.7 Example of Heart Rate Graphs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart(rate(graphs(from(a(single(participant(completing(a(single(HIIT(session((top(panel)(
and((a(single(participant(completing(a(single(MIT(session((bottom(panel)(as(recorded(by(
Suunto(Ambit2(S(heart(rate(monitor((Suunto(Oy,(Vantaa,(Finland)(
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5.8  Changes in V̇O2peak in CRC survivors following an exercise intervention – 
A comparison of the present study and Sellar et al. 
 
 
 
  
 Baseline 4 weeks 8 weeks 12 weeks 4 week Change 
Endpoint 
Absolute 
Change# 
Present 
Study * 
(mL.kg-1.min-
1) 
21.1 (3.6) 26.7 (9.9) 27.0 (7.5) - 6.1 (7.0) 8.0 (6.5) 
Sellar et al. 
^ 
(mL.kg-1.min-
1) 
22.5 (6.7) - - 25.5 (7.0) - 3.0 (1.4 to 4.6)  
*Values expressed as medians (IQR) 
^Values expressed as means (95% confidence intervals) 
#Endpoint for present study = 8 weeks; endpoint for Sellar et al. = 12 weeks. 
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5.9 Participant Information Sheet 
 
 
 
 
 
 
 
Participant3Information3Sheet3
 
 
The Effects of High Intensity Interval Training on Interleukin-8 in Colorectal 
Cancer Survivors 
 
Principal Investigator:  
Gareth Hughes, BExSS (Hons)  MPhil Candidate, School of Human 
Movement Studies  
   E-mail: g.hughes4@uq.edu.au     
   Phone: 0407 141 555 
Co-Investigators:  
Andrew Sax, BExSS (Hons)  PhD Candidate, School of Human 
Movement Studies 
Kate Bolam, BScApp (Hons)            PhD Candidate, School of Human 
Movement Studies 
A/Prof David Jenkins, PhD, MSc, BA  Lecturer, School of Human Movement 
Studies 
Dr Tina Skinner, PhD, BScApp (Hons) Lecturer, School of Human Movement 
Studies  
Professor Suzanne Chambers, PhD   Australian Research Council Future 
Fellow, Griffith University 
Professor Jeff Dunn   CEO, Cancer Council Queensland 
Dr Joanne Aitken  Director of Research, Cancer Council 
Queensland  
    
       
  
Why are we conducting this study? 
Research has found that people who have previously had Colorectal Cancer are at 
heightened risk of disease recurrence. Pleasingly, physical activity has been 
associated with a decrease in this risk, especially that of higher intensities.  However 
researchers are yet to investigate how exercise training at different intensities can 
influence important biological markers of Colorecal Cancer.  We wish to assess this in 
an effort to develop guidelines for the best type and intensity of exercise for the health 
of colorectal cancer survivors. 
 
Are3you3eligible3to3participate3in3this3study?3
 
We require 15 males and females who have been diagnosed with Colorectal Cancer.  
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Participants must not have any musculoskeletal, neurological, respiratory, or 
cardiovascular conditions that prevent them from safely completing the exercise 
demands of the study. Participants will also be excluded if they are receiving 
pharmacological treatment to increase their insulin sensitivity and/or exogenous 
insulin therapy. In addition, volunteers will need to obtain consent from their doctor 
(GP) before participating in the study 
What3does3the3exercise3program3involve?3
 
Participants will be randomly assigned to one of two groups: (1) high intensity 
aerobic interval training or (2) moderate intensity aerobic continuous training. Both 
groups will exercise three times per week for 8 weeks.  All sessions will be completed 
on stationary bicycles. 
 
High intensity groups will exercise at 90% of their maximum capacity for 4x4minute 
intervals, interspersed by 3 min periods of recovery at a lower intensity. Moderate 
intensity groups will exercise at 70% of their maximum capacity for the duration of 
the session (50 minutes). All high intensity interval exercise sessions will include a 
10min warm-up and 5min cool-down. With warm-ups and cool-downs, each exercise 
session will last approximately 60 minutes in total.  
 
All exercise sessions will be undertaken at the School of Human Movement Studies 
on The University of Queensland’s St Lucia campus. All sessions will be conducted 
in small groups of 3-4 participants under direct supervision of a qualified exercise 
physiologist.  
 
The type of exercise training used in this study has been previously investigated in 
clinical populations including patients with heart failure and type 2 diabetes. No 
adverse events were reported in these trials; high intensity exercise training is safe to 
use in this population. Blood pressure, heart rate and perceived exertion will be 
monitored during exercise testing and training sessions to further ensure the safety of 
all participants. 
 
What will testing involve? 
We will conduct a testing session before you start training, half way through your training (4 weeks), 
and at the end of your training (8 weeks) to track any differences. All testing will be completed by an 
accredited exercise physiologist trained to conduct each measure. Testing sessions take approximtaely 
1.5 hours to complete and you will need to be 12-hours fasted piror to each session (water is fine).  
Body3composition3
• Height and body weight.   
 
• Muscle and fat mass of the whole body will be measured by dual energy x-ray 
absorptiometry (DXA), a routine technique for the measurement of body 
composition.  You will lie on a specially designed table (as shown in the adjacent 
photo) for approximately 7 minutes and a scanning arm will move above your 
entire body.  
 
There is no pain or discomfort associated with these measures. 
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Cardiorespiratory (aerobic) fitness  
• Aerobic fitness will be measured via a maximal cardiorespiratory fitness test. The 
test will involve cycling on an exercise bike for 10-15 minutes whilst you breathe 
through an apparatus that measures your oxygen consumption (as shown in the 
adjacent photo).  
 
Blood Analysis: Biomarkers of colorectal cancer growth 
• Blood will be sampled for us to assess biological markers that have been linked to 
Colorectal Cancer growth. All blood will be sampled and be analysed at The 
University of Queensland’s School of Human Movement Studies biochemistry 
laboratory by a qualified phlebotomist. You will be required to avoid food and 
drink (except water) for twelve hours before those sessions where your blood will 
be sampled.  
 
Questionnaires  
• Levels of self-reported physical activity will be assessed by the leisure score index 
from the Godin Leisure-Time Exercise Questionnaire that you can complete at 
home. Dietary information will be collected using a 3-day food diary. 
 
Are there any risks associated with being involved in this study? 
DXA uses very low energy x-rays to determine body composition and bone mass. The 
total dose associated with the scans you will undergo in this study is approximately 12 
µSv.  In comparison, an individual receives approximately 7 µSv for daily natural 
background exposure, 80 µSv for a return trans-Pacific flight, 100 µSv for a chest x-
ray, and 2000 µSv for a lumbar spine x-ray.  Therefore, although radiation is used in 
the scan, the amount of radiation is very small and the corresponding risk from 
participating in this study is extremely low.   
It is possible that some initial muscle soreness may result from testing and training; 
however, all participants will undertake a warm-up prior to, and cool-down 
immediately following each session. In the event that an emergency occurs, medical 
assistance will be available from the university health service according to our 
established emergency procedures. 
Lastly, the discomfort associated with the blood drawing procedures is minimal. 
There is a risk that bruising and infection may occur and that the arm might become 
sore.  Risk of bruising or infection from the blood draws will be minimized because 
all blood will be sampled by a trained phlebotomist. The total amount of blood drawn 
during each testing session will not exceed 6mL, is equivalent to approximately 1 
teaspoon. No syringes, lancets, needles or other devices capable of transmitting 
infection from one person to another shall be reused.  All of these items, which are 
disposable, will be destroyed after each use. As an additional safeguard in preventing 
contamination, new disposable gloves will be worn for all blood draws. All 
contaminated items will be disposed of promptly in sharps containers. 
 
All information will be strictly confidential and kept safely locked in a filing cabinet 
in the principal investigator’s office. Should publications result from this study, no 
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reference will be made to any individuals.  There is no financial reimbursement for 
participating in this study. On completion of the intervention and measurements, a 
summary of study findings and individual results will be made available to all 
participants.  
 
 
PARTICIPATION IS VOLUNTARY AND SUBJECTS ARE FREE TO 
WITHDRAW FROM THIS STUDY AT ANY TIME, FOR ANY REASON. 
 
This study has been cleared by one of the human ethics committees of the University 
of Queensland in accordance with the National Health and Medical Research 
Council's guidelines. You are of course; free to discuss your participation in this study 
with project staff (Gareth Hughes contactable on 0407 141 555). If you would like 
to speak to an officer of the University not involved in the study, you may contact the 
Ethics Officer on 3365 3924.  
 
 
 
Thank you for your interest in this study. 
 
 
